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Head and neck squamous cell carcinoma (HNSCC) is the sixth most common 
cancer worldwide and has a dismal 50% survival rate. Treatment for HNSCC is expensive 
and aggressive; surviving patients are left with significant physical impairment and 
emotional burden. Despite limited therapeutic options and poor survival, no novel 
effective therapy has been developed in 50 years. Perineural invasion (PNI) is a 
prognostic factor of poor survival in multiple cancers, including HNSCC, prostate and 
pancreatic cancers. If PNI is detected in HNSCC, the survival rate drops to 20%. Despite 
this alarming statistic, PNI is one of the least studied cancer phenotypes. Long-thought 
to be a passive process, new evidence demonstrates that PNI is an active process where 
tumor cells must degrade multiple layers of perineural sheath to spread. PNI leads to 
sensory disturbances including numbness, formication and cancer-associated pain. The 
nerve-tumor crosstalk necessary to promote PNI is understudied due to the lack of 
appropriate models that allow observation of nerve-tumor interactions.  Due to this deficit 
in investigations no anti-PNI therapies are available. In this study, we present a novel in 
vivo model of PNI to characterize interactions between nerves and tumors. This model 
uses the chicken chorioallantoic membrane in vivo platform with a grafted human HNSCC 
cell line adjacent to an implanted rat dorsal root ganglion. Mechanistic studies indicate 
that the neuropeptide galanin (GAL) mediates nerve-tumor crosstalk via activation of 
galanin receptor 2 (GALR2), a G-protein coupled receptor. Nerves initiate PNI via release 
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of GAL, which induces GALR2 on cancer cells. Through a novel signaling mechanism of 
tumor progression, activated GALR2 induces nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 2 (NFATc2)-mediated transcription of GAL and 
cyclooxygenase-2 (COX2) in cancer. Prostaglandin E2, a conversion product of COX2, 
promotes invasion of cancer cells and in a feedback loop, GAL promotes tumor 
neuritogenesis. Clinical data show that expression of proteins involved in this cascade 
are correlated with poor survival. Importantly, the GALR2 inhibitor M871 blocks PNI in the 
CAM in vivo model. This study provides evidence of the dynamic interaction between 






Part I: The Role of Invasion in Head and Neck Cancer Progression 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
in the world (1). In the United States, HNSCC accounts for more deaths each year than 
cervical cancer, melanoma, or Hodgkin's lymphoma and costs more than 2 billion dollars 
to treat (2, 3). Since patients with HNSCC often present with late stage tumors, the 5-year 
survival rate is only 50%, which is poorer than breast cancer or melanoma (4). Poor 
survival can be attributed to the high frequency of local recurrences, second primary 
tumors and distant metastases (1). Understanding the process by which tumor cells 
destroy the basement membrane, invade and metastasize is essential in controlling 
recurrence of HNSCC. Moreover, understanding these mechanisms of invasion and 
targeting key molecular factors facilitating this process will advance HNSCC treatment 
strategies and improve survival. 
The basement membrane is the first and most robust structural barrier to invasion 
(5). In normal and pre-cancerous mucosa, the basement membrane separates surface 
stratified squamous epithelium from the underlying connective tissue. Destruction of the 
basement membrane and invasion of genetically and phenotypically altered cells into the 
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underlying stroma are required for progression of epithelial dysplasia (pre-cancer) to 
HNSCC (Figure I.1). Epithelial dysplasia exhibits less organization than normal oral 
epithelium (pre-cancer) due to accumulation of genetically altered cells above the 
basement membrane. After destruction of the basement membrane, tumor cells invade 
locally or metastasize to distant sites. Tumor spread contributes to the lethality of the 
disease.  
A process contributing to invasion that has recently become a research-intensive 
area is epithelial-mesenchymal transition (EMT). Appendix A summarizes the molecular 
biology findings of EMT in HNSCC, and Appendix B summarizes our findings of a novel 
biomarker, cadherin-11, that may play a role in EMT in HSNCC. It is possible that blocking 
EMT may be an important future treatment strategy to control tumor spread and improve 
survival for HNSCC patients. 
 
Perineural Invasion: an Understudied Route of Tumor Spread 
Although repeatedly shown to be a critical metric of prognosis in many cancer 
types, perineural invasion (PNI), which is a subset of invasion, is undervalued and 
understudied. PNI is the pathologic invasion of cancer cells into the perineural space of 
nerves and is a mode of tumor metastasis that is independent of vascular or lymph node 
involvement (6). PNI is prominently associated with HNSCC, cutaneous, rectal, biliary 
tract, pancreatic, stomach and colon cancers (7). PNI is associated with sensory changes 
including paresthesia, pain and formication, or the feeling of insects crawling under the 
skin (8). PNI was identified in case reports in the medical literature by the mid-1800’s, 
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including a clear description of cancer of the lip spreading to the brain (9). By the 1950’s 
it was recognized that cancers with PNI were particularly prone to recurrence and 
resistance to chemotherapy (10). PNI has received little research attention, in part due to 
the long-held misconception that PNI is a passive process by which tumor cells within the 
perineural sheath simply spread along the path of least resistance, and for that reason 
PNI has sometimes been referred to as neurotropic carcinomatous spread or perineural 
spread (7). Recent evidence suggests that PNI is much more likely an active process 
involving mutual tropism of the tumor and nerve.  
 
Part II: Diagnostic and Research Challenge Associated with PNI 
There are several reasons why the major mechanisms that initiate and sustain PNI 
remain unknown. Although determined to be an independent prognostic factor in several 
cancers, PNI is underappreciated compared to some more widely accepted prognostic 
factors such as lymph node involvement. Therefore, there is a lack of consistent staining 
for nerves in histopathological examination of specimens, leading to frequently missed 
diagnoses. The lack of consistency of PNI detection and reporting methods has made 
retrospective clinical studies challenging to conduct and interpret. Due to wide variations 
in neurotropism and anatomical features of various cancer types, specific and evidence-
based PNI reporting guidelines should be determined for each cancer type. Importantly, 
a precise definition of PNI and how to report and interpret the extent of neuronal 
involvement has not been developed for most cancers.  
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The histological appearance of nerves makes PNI a difficult diagnosis from 
hematoxylin and eosin staining. In normal peripheral nerve anatomy, nerve fibers or 
axons and associated Schwann cells are surrounded by collagen fibers and fibroblasts 
that form a tube called the endoneurium, and bundles of nerves are termed fascicles, 
which are surrounded by a dense fibrous network called the perineurium (11). Cells of the 
perineurium are concentrically arranged around nerve fascicles and have an elongated 
shape and spindle-shaped nuclei. The perineural space lies between the fascicles and 
the perineurium. When nerves in tissue specimens are cut tangentially, nerve fibers 
appear long and wavy usually with an elliptical or oval shape. If nerves are cut in cross 
section, the nerve axons appear as small spheres with round nuclei. Due to processing 
artifacts the perineurium may appear exaggerated or not intact in both tangential or cross 
sections. Given the very complex microanatomy of peripheral nerves, histopathologic 
detection of PNI is very challenging, particularly with subtle microscopic presentations 
(12). PNI may be missed at tumor margins and in tangential sections of nerves. 
Additionally, PNI is more likely to be reported in larger nerves than in smaller nerves (12). 
PNI in small nerves at the margins of tumors is thought to play a large part in local tumor 
recurrence, while invasion of larger nerves may play a bigger role in distant tumor spread. 
PNI may also be missed because small nerves may be masked by tumor islands and 
inflammation (7). 
In addition to histopathologic, or “incidental” detection of PNI, PNI can be 
determined clinically from pain, paresthesia or motor dysfunction reported by patients 
(13). PNI can result in relentless pain and sensory disturbances including formication; 
clinical symptoms of PNI are correlated with very poor outcome (14). PNI may be detected 
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through imaging modalities such as MRI, and metastases may be mapped intracranially 
(15). On MRI, PNI may appear as neural enhancement or thickening. PNI usually occurs 
toward the CNS (retrograde), but can also occur in the anterograde direction. Because of 
the likelihood of skip lesions, it is important to view the entire course of a nerve with 
imaging (13).   
PNI of head and neck cancers have been reported to spread along peripheral 
nerves as far as 15 cm from a primary tumor (16). Since surgery remains a key 
component of cancer therapy, it is essential to appreciate the complications that arise 
from attempting to track and eliminate PNI. Anatomically, PNI of HNSCC usually occurs 
along the trigeminal and facial nerves, but has also been reported along the sixth cranial 
nerve (17) and greater auricular nerve (18). Innervation of multiple facial structures and 
extensive branching and interconnection of these nerves provides conduits for 
widespread tumor metastases (13). For example, connections exist between the 
trigeminal and facial nerves, such as at the greater superficial petrosal nerve which 
branches from the facial nerve and passes through the pterygopalantine fossa and there 
joins branches of the maxillary branch of the trigeminal. It may be at connections such as 
these that tumor cells traveling along nerves scatter to locations of the head and neck 
that are very difficult to predict or resect. 
Due to the extensive branching and possibilities of interconnections between 
nerves of the head and neck, along with the possibility of distant tumor spread and 
retrograde and anterograde movement of tumor along the nerves, it becomes extremely 
complicated to attempt to anatomically trace the path of PNI of a tumor. Unfortunately this 
tracing is essential to eliminate recurrence using surgical or radiation therapy, which are 
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the current major treatments for HNSCC. This challenge may explain the high incidence 
of locoregional recurrence that has been noted in HNSCC (1); current treatment 
strategies have not effectively improved survival in about 50 years. Locoregional 
recurrence may be in part because clinicians are missing tumors that have undergone 
complicated local and regional spread along nerves (6), which may be underappreciated, 
underreported and undertreated. Since imaging technologies are not sensitive enough to 
adequately track PNI through the extensive nerve system, the best way to address this 
problem may be to generate specific anti-PNI therapies that target tumor cells that have 
spread along nerves. 
 
Part III: Understanding Biomarkers and Mechanisms to Direct Future Anti-PNI 
Therapies 
PNI is understudied in part due to the scarcity of appropriate research models.  
Almost all investigations of PNI are retrospective studies that compare PNI status and 
outcome. Due to inconsistencies in reporting and detecting PNI, it is nearly impossible to 
draw meaningful conclusions from the bulk of these studies, and therefore clinicians are 
calling for more research that will lead to improved management of tumors with PNI.   
Only a few clinical studies evaluated PNI molecularly and mechanistically.  Table 
I.1 lists several studies that have involved investigation of specific biomarkers with 
immunohistochemistry or in-situ-hybridization in different cancers with PNI. In addition to 
immunostaining of tumor specimens, clinical investigators have also used some 
molecular biology methods to investigate potential biomarkers of PNI, including gene 
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expression profiling of whole tumors (19) or laser capture microscopy with direct 
sequencing (20). 
Some researchers have shown that neuronal signaling pathways may drive PNI 
by facilitating nerve-tumor crosstalk. A few molecular targets that have been studied 
include the neuronal cell adhesion molecules L1-CAM (21) and NCAM (22-24), and 
growth factor/receptor pairs NGF/TRK-A and NGF/TRK-B (25-29). Our laboratory has 
identified the neuropeptide/receptor pair galanin (GAL)/galanin receptor 2 (GALR2) as 
having an oncogenic role in HNSCC (30). Although evidence supports that GAL/GALR2 
promotes tumor growth, the role of this neurotrophin/receptor pair has not been 
investigated in invasion or more specifically, PNI. The studies presented in the 
subsequent chapters will investigate the role of GAL/GALR2 in tumor progression. 
 
Basic Science Methodology for PNI Investigation 
The importance of studying PNI is recognized but challenges with in vitro and in 
vivo models have seriously hampered studies of PNI mechanisms. Early attempts at 
understanding the molecular mechanisms emphasized that modeling PNI in the 
laboratory is very challenging. These basic science investigations of PNI reflect the 
confusion seen in clinical studies.  
Of the rudimentary attempts at re-creating PNI in vitro or in vivo, few models are 
able to simultaneously capture the interaction of the tumor and nerve. There is clinical 
and in vitro evidence that PNI involves reciprocal interaction between cancer cells and 
nerves; nerves respond to factors secreted by cancer cells. These factors are also 
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important in physiologic processes during development and response to injury. Table I.2 
summarizes existing laboratory methodologies that model PNI. Most in vitro assays are 
simply modifications of traditional cancer assays and do not demonstrate the complexity 
of neuronal interactions with cancer. Most in vivo models have involved direct injection of 
cancer cells into nerves, thereby bypassing the initial steps in the invasive process. Due 
to these deficiencies, the emphasis of research has been on the role of the tumor in 
initiating and sustaining PNI, while little attention has been given to the active role of 
nerves in this process.  
 
Part IV: Problem Statement 
Deficiencies in clinical detection, reporting and researching PNI have resulted in a 
gap of understanding of this deadly pathologic process. Lack of understanding of PNI has 
hindered the development of targeted therapy. When PNI is detected, clinicians often opt 
for aggressive adjuvant therapies for lesions that may be treated more effectively and 
conservatively with a therapy that targets PNI. Therefore, research aimed at 
understanding PNI will lead to novel therapies and improved treatment protocols to 
address this dangerous phenotype of HNSCC. Ultimately, improved understanding of the 
molecular biology of PNI, including markers of perineural involvement in profiling tumors, 
will assist clinicians and scientists in developing personalized medicine strategies to treat 
patients. 
Current management of neurotropic cancers such as HNSCC is insufficient.  Due 
to complicated invasion patterns, HNSCC with PNI cannot be managed with surgery and 
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radiation alone. Therefore, it is essential to develop anti-PNI therapeutics in order to kill 
cancer cells protected from existing treatments by invasion along the nerves with 
subsequent loco-regional recurrence. The shortfalls of current PNI models critically limit 
research advances in this area. Our hypothesis is that the GAL/GALR2 signaling 
mechanism promotes PNI; however more advanced models are necessary to test the 
relevance of this interaction. Therefore, the aims of this dissertation are: 1) to develop 
novel models of PNI and 2) to use these models to mechanistically investigate the role of 





Figure I.1: HNSCC progression. Normal epithelium consists of cells with low mitotic 
activity separated from the connective tissue with an intact basement membrane. In 
epithelial dysplasia and carcinoma-in-situ (full thickness epithelial dysplasia), abnormal 
epithelial cells appear above the basement membrane. In HNSCC, the basement 




Protein Type Biomarker Cancer Type and Reference(s) 
Antigen LEU7 Adenoid Cystic (31) 
Actin-Binding DSTN Pancreatic (32) 
Neuronal Cell Adhesion L1-CAM 
NCAM 
Prostate (21)  
Bile Duct (22) 
Gallbladder (23) 
Squamous Cell (24) 
Cell Surface Receptor FAS Pancreatic (33) 
Cytokine TGF-β1 Prostate (34) 
 CXCL4/CXCL12 Prostate (35) 
Cytoplasmic BYSL Prostate (36) 
 CTTN Laryngeal (37) 
 MUC1/SIGLEC4 Pancreatic (38) 
Golgi Membrane MT Prostate (39) 
Growth Factor/Receptor NGF/TRK-A/B HNSCC (25) 
Basal and Squamous Cell (26) 
Pancreatic (27-29) 
Kinase RET/GFR1α Bile Duct (40) 
Lens CRYαβ Squamous Cell (41) 
microRNA mir-224 Prostate (39) 
Microtubule associated MAPRE2 Pancreatic (42) 
Motor KIF14 Pancreatic (43) 
Neurotrophic GDNF Bile Duct (40) 
Pancreatic (44) 
Protease MMP2 Prostate (35) 
 MMP9 Pancreatic (44) 
Prostate (35) 
Proteoglycan SDC2 Pancreatic (45) 
 GPC1 Pancreatic (44) 
Receptor CXADR Prostate (39) 
Rho-Associated ARHGDIB Pancreatic (43) 
Scaffolding CAV-1 Prostate (34) 
Transcription Factor c-MYC Pancreatic (33) 
 NF-κB Prostate (46) 
 
Table I.1: Biomarkers of PNI confirmed with immunohistochemistry.  
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In vitro assays Neural Monolayer Adhesion  (47, 48) 
 Boyden Chamber  (40, 49-52) 
Immunoblot or proteomic analysis 
of cell lines with high or low PNI 
(51, 53) 
Neuroplasticity  (51, 54, 55) 
Dorsal Root Ganglion or 
Myenteric Plexus Co-Culture with 
cancer cells 
(51, 52, 54, 56-61) 
Genetic profiling of nerve-invasive 
clones 
(43) 
Live Cell Imaging (54) 
In vivo assays Mouse xenograft models (51, 53, 62) 
 Sciatic nerve injection (52, 59-61) 
Murine model with human nerve 
plexus graft 
(63) 
Genetic profiling of high/low PNI 
groups 
(63-65) 
In vivo imaging (60) 
 






Models of HNSCC Progression 
Portions of Chapter II are adapted from previously published manuscripts (66, 67). 
 
Part I: Models of Invasion 
 The tumorigenic phenotypes or hallmarks of cancer include invasion and metastasis, 
proliferation, survival, angiogenesis, and stemness (68). Invasion is required for multiple 
steps in HNSCC progression including initiation, local spread and metastasis. During 
transformation of a precancerous lesion to HNSCC, cells invade from the surface 
epithelium, the tissue of origin of HNSCC, into the underlying connective tissue. Invading 
cells destroy the basement membrane that separates the epithelium from the connective 
tissue. Destruction of the basement membrane and invasion are essential for 
development of HNSCC. Thus, the basement membrane is the first, most robust 
structural barrier to invasion (5). Cancer cell proliferation and survival promote tumor 
growth. Angiogenesis facilitates tumor growth and spread, and stemness promotes tumor 
recurrence. Given the importance of these phenotypes in tumor progression, a robust 
cancer model should recapitulate these phenotypes. 
Many models have been developed in the last few decades to evaluate the oncogenic 
phenotypes of HNSCC. However, most of these models are in vitro systems that work 
with monolayer cultures, making these assays difficult to translate into clinical application. 
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Furthermore, these models do not recapitulate the basement membrane or the 
connective tissue. Due to the importance of invasion in tumor progression, we recently 
developed an in vitro three-dimensional  (3D) model for   human   HNSCC   as  described  
in  Appendix  C  (69, 70), that recapitulates stratification  of  the  surface  epithelium,  
destruction  of  the  basement  membrane  and invasion of tumor islands into the 
connective tissue. This oral cancer equivalent model is excellent for studying several of 
the local effects of invasion. However, the model does not simulate the systemic impact 
of invasion (e.g. metastasis) as may be observed in an in vivo murine model. Several 
murine models are used to study HNSCC. Sub-cutaneous injection models of tumor cells 
into immunocompromised mice are useful to study tumor size (71). The floor-of-the-mouth 
tumor models have the advantage of placing tumor cells into the oral tumor 
microenvironment and can lead to metastases (72). However, both models require 
injection of tumor cells below the basement membrane and do not replicate invasion. The 
mouse oral carcinogenesis model involves inducing tumors in mice through exposure to 
carcinogens in the water supply such as 4-nitroquinoline-1 oxide, which mimics the impact 
of tobacco exposure (73). This model is very useful to study both dysplasia and squamous 
cell carcinoma, but genetic studies are limited since the tumors produced are of mouse, 
not human origin.   
Unfortunately, most murine models of human HNSCC are inadequate because 
tumor cells are injected directly into the connective tissue thereby bypassing the 
basement membrane of the surface epithelium, the first barrier to invasion. Given the 
importance of invasion in tumor progression, we developed an in vivo model of human 
HNSCC progression utilizing the chicken embryo. The embryonic chicken is among the 
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most well-characterized and useful in vivo biological systems (74). The chorioallantoic 
membrane (CAM) assay is an emerging model of tumor progression using the embryonic 
chicken. The CAM is a very vascular structure that surrounds the chick embryo. It allows 
for exchange of dissolved O2 and CO2, similar to the function of the placenta of a 
developing mammal.  The CAM is comprised of an upper chorionic epithelium, intervening 
mesenchyme, and lower allantoic epithelium. The chorionic epithelium is structurally 
similar to human epithelium (66) and is separated from the underlying connective tissue 
by basement membrane comprised of collagen IV, similar to that observed in human oral 
mucosa. 
In the CAM assay, a small opening is made in the shell of a fertilized egg, allowing 
a tumor cell graft to be seeded directly on the chorionic epithelium. Grafted tumor cells 
invade through the basement membrane of the chorionic epithelium and into vascular 
structures in the underlying mesenchyme, thereby metastasizing to distant structures and 
organs including the liver of the developing chicken and the lower CAM (66).  
Figure II.1 provides an overview of the CAM model of HNSCC and identifies where 
HNSCC tumors grow, invade and metastasize within the chick egg. HNSCC cells are 
seeded on the upper CAM and destroy the basement membrane of the surface epithelium 
to invade the connective tissue and blood vessels via which they metastasize to the lower 
CAM and liver. Figure II.2 provides an overview of the procedure, and outlines the 
endpoint assays including tumor growth, invasion, angiogenesis and metastasis.  
  The CAM HNSCC in vivo model was validated by investigating the role of EZH2 
(enhancer of zeste homolog 2) in HNSCC growth, angiogenesis, invasion and metastasis 
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(Appendix D). Using this model, we recently showed that EZH2, a histone 
methyltransferase, promotes progression of HNSCC by inducing multiple cancer 
phenotypes, likely via methylation of multiple tumor suppressor genes (71, 75).  
The first tumor grafts on the CAM were successfully performed in 1913 using rat 
sarcoma tissue, establishing that the CAM is an appropriate recipient site for xenografts 
(76). This discovery led to the development of multiple carcinogenesis assays using the 
CAM, which have become prominent methods to assess tumor angiogenesis, 
progression and metastasis (77, 78). Although the basic technique of grafting tumors onto 
the CAM has changed very little, powerful technological advances allow scientists to use 
the CAM for assays of increasing complexity. These advances have led to renewed 
attention in this established model, particularly in the past decade (Figure II.3). Since 
2010, nearly 100 cancer-related publications using the CAM model have appeared 
annually in peer-reviewed journals listed on PubMed. 
Our laboratory recently reported the use of the CAM model to simultaneously study 
multiple aspects of HNSCC tumor progression, including tumor growth, invasion, 
metastasis and angiogenesis (66). Although the CAM model has been used to study oral 
epithelial dysplasia (precancer), peri-tumor lymphatic vessel density, and to test drugs for 
HNSCC, it had not been characterized as a comprehensive model for HNSCC 
progression until our recent study. The study and related phenotypes are summarized in 
Table II.1. The CAM model of HNSCC has several benefits over murine in vivo models.  
The CAM closely replicates the tissue complexity of oral mucosa, i.e. the basement 
membrane separating the epithelium from the connective tissue, and therefore is an 
excellent model for HNSCC progression. Most murine models of HNSCC require 
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subcutaneous or submucosal injection of cancer cells.  Because the injected cells 
artificially bypass the basement membrane, injection-based murine models cannot 
replicate destruction of the basement membrane with subsequent invasion. This 
important phenotype is an essential step for transformation of a premalignant lesion into 
HNSCC (79). However, in the CAM model of HNSCC, tumor cells must degrade the 
basement membrane of the chorionic epithelium to invade, closely replicating progression 
of precancerous lesions to HNSCC. Given that some recent work emphasizes the impact 
on invasion of structures and channels found in true extracellular matrix, the CAM model 
is attractive to study invasion in vivo (80, 81). 
Many technological advances are giving a fresh perspective on the value of CAM 
tumors. It is now possible to use stop-motion video-microscopy to continuously monitor a 
target’s activity over a period of days (82). Unlike traditional murine models, the CAM 
model is able to exploit the promise of these new techniques. While both murine and CAM 
models provide in vivo results, tumors on the CAM are more readily observed and 
quantified. For similar reasons, the CAM model also offers easier study of angiogenesis.   
Another advantage of the CAM model is the short duration (maximum 1 week) 
required to assess even late events in tumor progression, such as metastasis. This may 
take several weeks to months to assess in murine models (83). This long duration 
increases the cost and time required for investigations. The cost per mouse limits the 
number of mice that can be used for each experiment. The CAM model provides an 
opportunity to perform large in vivo experiments at a fraction of the cost of murine-based 
models of HNSCC. The cost effectiveness and easy accessibility of the CAM system 
enhance the appeal of this in vivo model, particularly when funding resources are limited. 
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 Importantly, the rapid turnaround of results in the CAM model allows in vivo 
studies with transiently transfected HNSCC cells, which cannot be performed in murine 
models. For example, the impact of an siRNA on downregulation of a protein lasts 7-10 
days for rapidly dividing cells (84). This timeframe is insufficient for tumor studies in mice, 
which take weeks to months. In contrast, in the CAM the entire sequence of tumor 
progression including proliferation, invasion and metastasis can be observed in this time 
frame. 
Another advantage of the CAM-HNSCC model is the late development of the 
immune system in the chick embryo (83). Due to the lack of an immune system in the 
early chicken embryo, the CAM system readily accepts many types of xenografts. Few 
cells are needed for xenograft experiments, and metastasis can be quantified very 
accurately through PCR-based methods (85). The CAM model of tumor progression has 
some limitations. Perhaps the most significant limitation is that the mouse is currently 
accepted as the gold standard for in vivo biological studies. Moreover, technical dexterity, 
and specific equipment/ materials are necessary to set up the CAM protocol. This is also 
true of some murine HNSCC models such as the tongue and floor-of-mouth models (72). 
The chick embryo becomes fully immunocompetent by day 18 (83). The 
developing immune system of the embryonic chicken limits the duration of a study with 
human tumor cells and the lack of an immune system prevents the investigation of tumor-
host immune system interactions. However, investigations of human HNSCC in mouse 
also require the use of immunodeficient mice. The larger sample sizes used for CAM 
experiments yield a wealth of data for multiple phenotypes requiring extensive time for 
analysis.   
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Overall, the scientific benefits of the CAM model make it an attractive option to all 
cancer biologists. The practical advantages of the CAM model over rodent models make 
it a cost-effective, accessible option to scientists in developing institutions. For these 
reasons, and because the CAM brings the study of these processes into a uniform setting 
where interactions can be examined, the popularity of the CAM model will continue to 
increase. 
 
Part II: Advancing the CAM Model to Become a Model of PNI 
The significance of the primed neural niche in the tumor microenvironment has been 
alluded to in histopathological observation and 3-dimensional (3D) reconstruction of 
tumors from labeled tissue sections (86). However, the speculated mechanisms of PNI 
have underplayed the role of neurons in tumor-nerve interactions, since previous in vitro 
models could not capture the dynamic involvement of neural tissue (7). Most in vivo 
studies of PNI focus on tumor spread and inhibition of motor function, and depend upon 
direct injection of tumor cells into sciatic nerves (87). Injection models are useful to show 
destructive tumor progression and pain resulting from tumor cells within nerves. In a 
different approach, surgically implanted orthotopic tumor grafts were used to characterize 
the importance of β-adrenergic receptors in promoting PNI and progression of prostate 
cancer, thus suggesting a more prominent role of neuritogenesis in tumor progression 
(88). However, in bypassing the invasive process using surgically implanted tumors, 
these previous models do not truly replicate PNI. 
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 The prevailing view is that cancer cells are the drivers of tumor-neuronal 
interactions, in part because limitations of previous in vivo models made it impossible to 
fully appreciate the role of nerves in these interactions (7). Given the shortcomings of 
previous in vivo PNI models, we developed a new PNI model on the CAM in vivo platform, 
rooted in work from the research team of Nobel Laureates Rita Levi-Montalcini and 
Stanley Cohen, and Victor Hamburger that demonstrates the ability of chicken embryos 
to sustain tissue grafts (89, 90). In this model, a mammalian dorsal root ganglion (DRG) 
is isolated and grafted onto the surface epithelium of the upper CAM. After the DRG 
becomes incorporated into the epithelium of the CAM, HNSCC cells are grafted near the 
DRG and allowed to interact with the nerve before the entire in vivo system is harvested 
and analyzed. Importantly, the system allows full visual observation of either the DRG or 
the tumor in vivo by fluorescent labeling. 
 In the early development of the CAM-PNI model, both mouse and rat DRG were 
tested for optimal incorporation into the CAM. We first performed a time course 
experiment with mouse DRG to determine the optimal number of days necessary for the 
graft procedure. We found that the mouse DRG becomes fully incorporated by day 3 
(Figure II.4A and Figure II.4B).  We also performed optimization using rat DRG (isolation 
technique shown in Figure II.4C) and found that rat DRG had even more reliable 
incorporation into the CAM epithelium than mouse DRG by day 3 (Figure II.4D).  
Therefore, rat DRG were selected for future model optimization. 
 Following optimization of the DRG grafting technique, we further adapted the 
model to study PNI in vivo. The CAM-PNI model was inspired by an in vitro assay of co-
culturing DRG with prostate cells in MatrigelTM (57). When using HNSCC cells in co-
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culture with rat DRG, we found that they exhibited robust invasion toward nerves in vitro 
(Figure II.5A). When a rat DRG was grafted adjacent to HNSCC tumor cells on the CAM, 
both were supported by the in vivo system (Figure II.5B) and within 2 days, HNSCC 
invasion into the nerve was observed  (Figure II.5C and Figure II.5D). 
Our CAM-PNI in vivo model addresses the deficits of previous models by 
demonstrating neuronal outgrowth into the peri-tumoral niche. Importantly, tumors in the 
CAM-PNI system are not surgically implanted, thereby maintaining the invasive process 
necessary for PNI. The system is also useful in studying therapy to disrupt PNI. In the 
future, the model could be used to evaluate response to treatment by measuring the 






Figure II.1:  Overview of the CAM model of tumor progression.  Fluorescently labeled 
cancer cells are seeded on the upper CAM of the chick embryo. The cancer cells invade 
the epithelium and basement membrane of the upper CAM and move through connective 
tissue into the vasculature. Cancer cells can metastasize to the lower CAM or liver and 





Figure II.2: Experimental procedure and timeline of the CAM assay. Fertilized 
chicken eggs are incubated at day 0. On day 8, the developing vasculature is identified 
and a window is opened on the egg to seed human cancer cells.  On day 11, the egg can 
be re-opened to harvest the upper CAM containing the tumor in order to assess tumor 
growth, invasion and angiogenesis. For metastasis studies, the egg is opened at day 16 
to collect the lower CAM and liver of the developing chicken. qPCR analysis of the 
collected tissues provides an estimation of the number of human cancer cells that have 




Figure II.3: The CAM emerges as a standard model of carcinogenesis. 
“Chorioallantoic membrane” and “cancer” were entered as search terms on PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed/), and the results were sorted by date of addition to 
PubMed database. The number of articles per decade was quantified, and Student’s t-
test was used to analyze the difference in the number of publications using the CAM 
method between decades. Between the 1970s and 1980s and beyond there is a 
statistically significant increase in the number of articles, and the largest increase 
occurred between the 1990s and 2000s (P < 0.05). Given this trend, it is likely that an 






Figure II.4: Optimization of nerve grafting on the CAM. A. Stereo microscope images 
show grafting of a mouse nerve on the CAM (arrows identify nerves). No integration of 
the nerve was observed after the first day, however by the second day there was partial 
integration, and complete integration of the nerve into the CAM by the third day after 
grafting. B. Histological images of the grafted nerve are shown for day 2 (partial 
integration) and day 3 (full integration). C. The procedure for opening a rat spinal column 
to collect DRG is shown. D. Full integration of a rat nerve at 3 days post grafting is shown 





Figure II.5: Optimization of the CAM-PNI model. A. HNSCC cells exhibit PNI when co-
cultured with a rat DRG in vitro. B. The co-culture approach is adapted to an in vivo 
system by co-grafting a rat DRG and HNSCC tumor cells onto a CAM (arrow highlights 
the nerve on the CAM). C. The upper CAM tissue is collected, and PNI is observed. D. 
Histologic images of PNI from the CAM co-grafting technique (20x and respective 40x 
images are shown). In images, “C” labels cancer and “N” labels nerves. Tumor cells, 




HNSCC Cancer Phenotype Studied Reference(s) 
Angiogenesis (66, 91-97) 
Biomarker Expression (66, 92, 93) 
Drug Testing (92-95, 98-101) 
Dysplasia Study (102) 
Invasion (66, 92, 96, 103-105) 
Lymphatic Vessel Density (106) 
Metastasis (99-101, 103, 107) 
Tumor Growth (66, 92, 93, 96, 108) 
 
Table II.1: The use of the CAM model in HNSCC research. The terms “chorioallantoic” 
and “head and neck cancer” were used to identify articles listed on Pubmed that use the 
CAM model to study HNSCC. The articles from the resulting search are organized 




Galanin Modulates the Neural Niche to Favor Perineural Invasion in Head and 
Neck Cancer 
Chapter III is adapted from a manuscript that is under review for publication (109). 
 
INTRODUCTION 
PNI predicts poor survival in head and neck squamous cell carcinoma (HNSCC), 
pancreatic, stomach and colon cancers (7). PNI is associated with pain and tumor spread, 
independent of lymph or vascular involvement (6). Previously assumed to be a passive 
process by which cancer spreads along the path of least resistance, recent evidence 
suggests PNI is an active process whereby tumor cells must degrade several layers of 
perineural sheath prior to metastasis (110). 
PNI is observed in up to 80% of HNSCC cases and correlates with tumor recurrence 
and spread (110, 111). HNSCC can spread along nerves into the brain or into sensory or 
motor nerves, and is associated with loss of function, pain, numbness and formication, 
i.e. the feeling of insects crawling under the skin (111). HNSCC with PNI is treated 
aggressively but the prognosis remains poor. Unfortunately, there is no targeted 
treatment for PNI since the molecular mechanisms are largely unknown. Therefore, 
dissecting the mechanism of PNI is a critical  area of research since this would  facilitate 
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the development of novel therapeutics targeting PNI. Specific treatment of PNI would 
enhance patient survival and quality-of-life. 
Although it has been suggested that the altered neural microenvironment adjacent 
to tumors contributes to cancer progression, the limitations of existing in vivo models of 
PNI have hindered elucidation of nerve-tumor interactions (7). To overcome this obstacle, 
we developed an in vivo model of PNI to characterize mechanisms of nerve-tumor 
interactions. We show that the neuropeptide galanin (GAL) initiates nerve-tumor crosstalk 
via the activation of the G protein-coupled receptor galanin receptor 2 (GALR2) on cancer 
cells. Our data reveal that activated GALR2 induces nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 2 (NFATC2)-mediated transcription of 
cyclooxygenase-2 (COX2) and GAL. COX2 enzymatically facilitates prostaglandin E2 
(PGE2) production, promoting tumor progression. In a feedback mechanism, GAL 
released by cancer induces neuritogenesis and facilitates PNI. These studies 
demonstrate that the nerve initiates PNI via GAL, providing a potential treatment target. 
Moreover, the novel approaches presented here provide a starting point to investigate the 
roles of other neurotrophic proteins in PNI. 
 
METHODS 
Cell Culture. HNSCC cell lines UM-SCC-1 (from Thomas Carey, University of Michigan) 
and OSCC3 (from Peter Polverini, University of Michigan) were genotyped to confirm cell 
types at the University of Michigan DNA Sequencing Core prior to all studies. HNSCC 
cells and the neuroblastoma cell line SH-SY5Y (from Stephen K. Fisher, University of 
Michigan) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco®, 11965-
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092) supplemented with 10% fetal bovine serum (FBS, Gibco®, 16000-044) and 1% 
PenStrep (Gibco®, 15140-122). UM-SCC-1 and OSCC3 cells were transfected with 
pcDNATM3.1 (InvitrogenTM, V790-20) and pcDNATM3.1-GALR2 (Missouri S&T cDNA 
Resource Center, GALR200000). Geneticin (Gibco®, 10131-027, 50 µg/mL) was used to 
select and maintain stable colonies. UM-SCC-1 and OSCC3 cells transfected with 
pcDNATM3.1-GALR2 were infected with control non-targeting small interfering RNA 
(siRNA, Dharmacon, D-001810-10-05) or siRNA targeting NFATC2 (Dharmacon, L-
003606-00) and COX2 (Dharmacon, LQ-004557-00-0002, siRNA sequences available in 
Table III.1). For stable NFATC2 knockdown, UM-SCC-1 and OSCC3 cells 
overexpressing GALR2 (UM-SCC-1-GALR2 and OSCC3-GALR2, respectively) were 
transduced with shRNA lentiviral particles (Thermo Scientific, shRNA sequences 
available in Table III.1). Stable colonies were selected using Puromycin (Santa Cruz 
Biotechnology, sc-108071B, 10 µg/mL for UM-SCC-1 cells and 25 µg/mL for OSCC3 
cells). 
 
Chromatin Immunoprecipitation (ChIP).  The EZ-Magna ChIP A/G kit (EMD Millipore) 
was used to perform ChIP as described (71). The sequences of the Ptgs2 (COX2) and 
Gal (GAL) primers used are provided in Table III.2. The Gal primers were designed by 
walking the promoter region of GAL and contain an AP-1 binding site. The Ptgs2 primers 
were reported previously and contain AP-1 binding sites (112, 113). The UM-SCC-1-
pcDNA and UM-SCC-1-GALR2 cells were grown to 60% confluence and cross-linked 
using 1% formaldehyde for 10 minutes, and then quenched with 0.125M glycine at room 
temperature for 5 minutes. The cells were lysed and also sonicated in order to fragment 
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the chromatin to 500 base pairs, then incubated overnight with antibodies and protein A 
or G magnetic beads. Crosslink reversal was achieved by incubating the chromatin for 2 
hours at 62°C and then the DNA was isolated. qPCR was used to analyse purified DNA 
to determine relative fold enrichment compared to input DNA. The ChIP antibodies used 
were anti-NFATC2 antibody (Santa Cruz Biotechnology, sc-7296) and control rabbit IgG 
(Dako, X0936) was used to normalize NFATC2-specific binding to background 
nonspecific binding.  
 
Data Analysis. GraphPad Prism (GraphPad software) was used for statistics. A 
Student’s t-test was performed with a P-value of <0.05 determined to be statistically 
significant. 
 
DRG Organ Culture. Rat dorsal root ganglia (DRG) and human HNSCC cells were co-
cultured in MatrigelTM Basement Membrane Matrix (BD Biosciences, 356234), similar to 
a described method (57). DRG were dissected from postnatal day 30 Sprague Dawley 
rats within 1 hour of being euthanized and placed in 15 µL of 4.6 mg/mL MatrigelTM. 
HNSCC cells (2 x 104) were seeded in an adjacent droplet of MatrigelTM, and cultures 
were immobilized by warming to 37°C and culturing in DMEM (DMEM, Gibco®, 11965-
092) supplemented with 10% FBS (Gibco®, 16000-044) and 1% PenStrep (Gibco®, 
15140-122). Cultures were maintained at 37°C with 5% CO2 for 2 days to observe cancer 
cell and neurite interactions. GALR2 inhibitor M871 or DMSO control was used at 100 nM 
in culture. GAL antibody and rabbit serum IgG were used at 3 ng/mL. Neurite extension 
and cancer cell movement were imaged after 48 hours and quantified using ImageJ 
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software (W.S. Rasband, NIH, Bethesda, MD; http://imagej.nih.gov/ij/). Cultures were 
made in quadruplicate and repeated in triplicate. 
 
Efforts to Reduce Bias.  Protocols were developed to eliminate investigator bias in 
quantifying samples. Quantification was routinely performed by 2 individuals, 1 of whom 
was blinded to the hypothesized outcome. Whenever possible, objective quantification 
methods, such as microplate readings and computer-based quantification of images were 
selected. 
 
Enzyme-Linked Immunoadsorbent Assay for PGE2.  CM from HNSCC cell lines UM-
SCC-1 and OSCC3 was collected and processed as described (114).  The total number 
of cells was quantified with a Countess® Cell Counter (InvitrogenTM, C10227). PGE2 was 
quantified as a surrogate for COX2 using a competitive ELISA (R&D Systems®, 
KGE004B) in 3 independent experiments per cell line. 
 
HNSCC-Neural Cell Interaction Assay. UM-SCC-1-pcDNA or UM-SCC-1-
GALR2 (1x104) cells were labeled with DiO, a dialkylcarbocyanine derivative, and 
suspended with 1x104 SH-SY5Y neuroblastoma cells that had been labeled with 
CellTracker Red CMPTX (Life Technologies, C34552) on 8-chambered cover-slips in 
blank DMEM in triplicate. After 24 hours, the cells were fixed, mounted and imaged at 60x 
magnification. Colocalization was quantified by counting the number of green HNSCC 
cells in contact with red SH-SY5Y cells and dividing by the total number of HNSCC cells 
per high powered field. Differentiation was quantified by counting the number of SH-SY5Y 
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cells with neurite extensions and dividing by the total number of SH-SY5Y cells present 
per high powered field.  
Human subjects. Paraffin-embedded human HNSCC tissues were used for 
immunohistochemistry analysis. The University of Michigan Institutional Review Board 
approved the protocol prior to any human tissue use.  All human tissues were de-identified 
prior to the study; therefore the University of Michigan Institutional Review Board 
determined that the research qualified for Category 4 Exemption status (Exemption 
Number 1999-0341).   
 
Immunoblot. Cells were lysed with 1% NP40 protein lysis buffer.  The following primary 
antibodies were used: anti-GAL (EMD Millipore, MAB374), anti-GALR2 (Alpha 
Diagnostics, GALR21-A), anti-actin (BD Scientific, 612656), anti-NFATc2 (Cell Signaling 
Technologies®, 5861), anti-COX2 (Cell Signaling Technologies®, 12282) and anti-
HNRNP (Santa Cruz Biotechnology, sc-15386).   Biotinylated anti-mouse and anti-rabbit 
secondary antibodies were used (Jackson ImmunoResearch Laboratories, 115-006-075 
and 711-006-152). The visualization of immunoreactive proteins was performed with the 
SuperSignal West Pico Chemiluminescent system (Pierce, 34080).   
 
Invasion Assay. Cell invasion was quantified 24-48 hours after siRNA transfection using 
Transwell inserts (Corning, 3422) and the modified Boyden chamber assay coated with 
MatrigelTM (BD Biosciences, 354230). Inserts that were not coated with MatrigelTM were 
used as a migration control, and invasion was normalized to migration according to the 
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manufacturer’s instructions by dividing the total number of cells that invaded through 
MatrigelTM by the total number of cells that invaded through the control insert. Five 
nanomolar GAL (Sigma-Aldrich®, G8041) or conditioned medium (CM) collected from rat 
DRG cultured in control medium for 48 hours was used as a chemoattractant in the bottom 
chamber of the assay. CM from rat DRG was incubated with 1:1000 anti-GAL antibody 
(EMD Millipore, AB5905) or rabbit IgG (Dako, X0936) for 1 hour at room temperature.  
Conjugated-GAL and unbound antibody or IgG were removed by centrifugation with an 
Amicon Ultra 50K centrifugal filter (EMD Millipore, UFC805024) for 10 minutes at 4000 
rpm.   
 
Immunohistochemistry and Immunofluorescence. Human and mouse tumors were 
stained with anti-COX2 rabbit monoclonal antibody (Cell Signaling Technology®, 12282), 
anti-S100 rabbit polyclonal antibody (Dako, Z0311, used to identify nerves on paraffin-
embedded tissue), cytokeratin AE1/AE3 mouse monoclonal antibody (Pan cytokeratins, 
EMD Millipore, IHCR2025-6, used to identify tumor cells on paraffin-embedded tissue), 
and anti-GAL rabbit serum antibody (EMD Millipore, AB5909). Mouse IgG (Dako, X0931) 
or rabbit IgG (Dako, X0936) was used at the same concentrations as the primary 
antibodies as negative controls. Biotinylated goat anti-mouse and anti-rabbit secondary 
antibodies were used (Biocare Medical, GM601H and GR608H). Hemotoxylin and eosin 
staining were performed to assess tumor morphology. Immunofluorescence on frozen 
CAM sections was performed using human collagen IV antibody followed by incubation 
with DAPI.  Immunofluorescent labelling of neurites was performed as follows: nerve 
explants were blocked with normal goat serum and incubated with anti-neurofilament (NF-
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M 160kD chain primary antibody (Zymed Laboratories®, 13-0700) in 0.3% triton X-100, 
followed by incubation with fluorescent anti-mouse secondary antibody (Jackson 
ImmunoResearch, 115-006-075). Imaging of representative fields was performed using 
an Olympus BX-51 microscope.   
 
Inclusion and Exclusion Criteria. In most in vivo and in vitro experiments, a normal 
distribution of samples was obtained. However, significant outliers were excluded from 
analyses if the values fell outside of a normal distribution. 
 
In vivo models. The University of Michigan University Committee on Use and Care of 
Animals approved all animal experiments.  
Mouse: Paraffin-embedded tissues from a previous animal experiment were used 
for these studies. As described (30), 1x105 OSCC3 cells stably expressing pcDNA-
GALR2 or control vector were suspended in MatrigelTM and injected on the backs 
of 4-6-week-old athymic mice (n=5, Ncr nu/nu strain, NCI, Frederick), so each 
mouse had an injection of each control and GALR2-overexpressing tumor cells. 
Animals were euthanized after 14 days. Out of the 5 animals injected, 3 palpable 
tumors were obtained from each group, so subsequent analyses were performed 
with n=3 samples for each control and GALR2 overexpressing tumors.  Each tumor 
generated was used for immunohistochemistry, PNI analysis and nerve 
quantification. Because previously collected samples were used, no power 
calculation was performed prior to analysis. 
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CAM Model: Twenty-four fertilized Lohmann White Leghorn eggs were obtained 
from the Michigan State University Department of Animal Sciences Poultry Farm 
for each experiment. After incubations, the eggs were randomly distributed into 
treatment groups of 6-8 eggs each, and tumor cells were seeded as described 
(66). Eggs that became contaminated during the experiment were excluded from 
analysis; additionally, CAMs that yielded tumors outside a normal distribution 
(significant outliers) were excluded due to likely seeding errors. 
 
In Vivo PNI Assay. DRG were dissected from rats within 1 hour of euthanasia and 
labeled using CellTracker Red CMTPX (InvitrogenTM, C34552). DRG were seeded on the 
CAM with fluorescently-labeled HNSCC cells. The CAM was harvested after 48 hour and 
tumor spread and neurite outgrowth were imaged using a Leica Stereo microscope and 
quantified using ImageJ. 
 
Neurite Outgrowth Quantification Assay. The Neurite Outgrowth Assay Plus kit (EMD 
Millipore, NS220) was used according to the manufacturer’s instructions. CM collected 
from human HNSCC cells was incubated with anti-GAL IgG (EMD Millipore, AB5909) or 
control rabbit IgG (Dako, X0936) for 1 hour at room temperature. Conjugated GAL and 
unbound IgG was removed by centrifugation with an Amicon Ultra 50K centrifugal filter 
(EMD Millipore, UFC805024). The CM was then used as a chemoattractant in the bottom 
chamber of the assay. SH-SY5Y human neuroblastoma cells were cultured in DMEM 
(DMEM, Gibco®, 11965-092) overnight and then 1x104 cells were seeded in the top 
chamber of the assay. After 48 hours, neurites were imaged at 10x and stained using the 
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stain in the Neurite Outgrowth Assay Plus kit, and retained proprietary AXIS kit dye was 
solubilized and quantified using a SpectraMax Pro 5 microplate reader (Molecular 
Devices). 
 
OncomineTM Analyses. The OncomineTM database (Compendia BioscienceTM) was 
used to collect clinical data used in meta-analyses. For comparison across 16 HNSCC 
datasets, a list of neuropeptides was generated based on extensive signalling roles within 
and outside the neuronal system (110, 115). Because PNI status is not included in the 
available OncomineTM datasets, survival was used as a surrogate indicator of potential 
PNI status since PNI is correlated with poor survival (6). Each neuropeptide was 
evaluated for expression in cancer versus normal tissue and also for 3-year survival 
versus 3-year death. The studies were dichotomized to 0 and significant studies at the 
5% level were assigned a value of 1.0 while insignificant studies were assigned a value 
of 0. The set was then subjected to a one-sample t-test against a 0.05 expected value.  A 
similar meta-analysis was completed for COX2 expression in cancer versus normal 
across 16 HNSCC datasets. Datasets used and their references are listed in Table III.3. 
 
Proliferation Assay. Human HNSCC cells (1x104) were seeded in triplicate in a 24-well 
plate. The total number of live cells was quantified every 24 hours using trypan blue 
(InvitrogenTM, T10282) and a Countess® Cell Counter (InvitrogenTM, C10227). 
 
Randomization.  An effort was made to randomize samples whenever possible in in vivo 
and in vitro experiments. Chicken embryos were randomized into treatment and control 
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groups. Additionally, rat nerves were randomly selected for explant experiments. Mice 
were not randomized since each mouse received the same 2 injections (one of control 
cells and one with GALR2-overexpressing cells).   
 
Sample Size Calculations. For CAM experiments, at least a 2-fold difference in tumor 
size, invasion and metastasis was predicted. Therefore with α of 0.05, power at 0.8 and 
coefficient of variation at 0.5 (low due to very consistent tumor seeding and incubation of 
all samples), at least 3 CAMs (eggs) per group was determined to be the minimal sample 
size. We used 6 CAMs (eggs) per group in each experiment. For in vitro experiments, it 
was similarly predicted that there would be at least a 2-fold difference in parameters 
studied with low variance, so with the same equation described above, we determined 
that using 3 replicates per in vitro experiment was appropriate. In vitro experiments were 
also repeated in triplicate. 
 
RESULTS 
GALR2 Promotes Tumor Progression 
OncomineTM was used to identify neurotrophic factors involved in tumor 
progression. Meta-analyses were conducted to compare the expression of neurotrophins 
and neuropeptides in HNSCC and normal samples (Table III.4). GAL and brain-derived 
neurotrophic factor were significantly overexpressed in HNSCC. Importantly, GAL 
expression correlated with poor clinical outcome in 38 analyses of clinical samples from 
multiple cancers (Figure III.1A) and with positive lymph node status and recurrence in 
HNSCC (Figure III.1B). 
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The neuropeptide GAL is a ligand for 3 G protein-coupled receptors: GALR1, 
GALR2 and GALR3. GALR2 is pro-proliferative (30) and is overexpressed in HNSCC due 
to a frequent chromosomal translocation (116). Previously, we showed that GALR2 
induces tumor growth in vivo (30). Using sections from these murine tumors, we found 
that PNI occurs in GALR2-overexpressing tumors but is absent in controls (Figure III.2A).  
Additionally, more nerves were present adjacent to GALR2-overexpressing murine 
tumors (Figure III.2B), suggesting that GALR2 induces neuritogenesis. Using DNA copy 
number, we found that high GAL predicted death at 3-years (Figure III.2C). In human 
HNSCC biopsy specimens (demographic data available in Table III.5), GAL was 
expressed in cancer adjacent to nerves (Figure III.2D).  
Invasion is essential for regional spread and metastasis. Since HNSCC tumors 
expressing high levels of GAL are correlated with lymph node metastases and recurrence 
(Figure III.1B), we hypothesized that GAL may promote invasion via GALR2. To 
investigate this possibility in 2 independent HNSCC cell lines, we used the Boyden 
chamber assay with GAL as the chemoattractant. Invasion was greater in cells 
overexpressing GALR2 compared to controls (Figure III.3A and Figure III.4A). Using 2 
cell lines in the chick embryo CAM model of HNSCC, GALR2 promoted aggressive tumor 
growth and invasion in vivo. Tumors overexpressing GALR2 were larger (n=6 for each 
group, Figure III.3B and Figure III.4B) and more invasive (Figure III.3C and Figure 
III.4C; n=6 for each group) than controls, and destroyed the CAM basement membrane 
(Figure III.3D and Figure III.4D). Additionally, UM-SCC-1-GALR2 tumors metastasized 
more frequently to the lower CAM and liver of the embryos than the corresponding control 
tumors (Figure III.3E; n=3 for each group). 
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GALR2 Induces PNI 
Since the murine studies described above showed strong correlation between 
GALR2 and PNI, we investigated the impact of GALR2 on PNI with additional models of 
neural-tumor interactions. UM-SCC-1-GALR2 co-culture with SH-SY5Y human 
neuroblastoma cells led to neuritogenesis and co-mingling of the cells, which were 
significantly increased compared to control (empty vector) cells (Figure III.5A). Since SH-
SY5Y is a neural tumor cell line, we also investigated GALR2-mediated interactions 
between normal neural tissue and HNSCC using rat dorsal root ganglia (DRG) explants 
co-cultured with HNSCC cells.  Both HNSCC-GALR2 cell lines tested were more invasive 
toward DRG and induced more neuritogenesis than control cells (Figure III.5B and 
Figure III.6A). 
The role of the nerve in tumor progression is relatively unknown due to the lack of 
appropriate in vivo models to characterize nerve-tumor interactions. To address this 
deficiency, we developed an in vivo model of PNI that demonstrates tumor 
neuritogenesis. Briefly, a rat DRG was grafted onto the CAM and incorporated into the 
connective tissue. Subsequently, human HNSCC cells were introduced adjacent to the 
DRG. The grafted DRG was nourished by the developing vasculature of the CAM that 
replicates the pro-angiogeneic microenvironment observed in carcinogenesis. Tumor-
nerve interactions were observed and quantified. Tumor cell movement and neurite length 
were higher with HNSCC tumors overexpressing GALR2 than control tumors in both cell 
lines (Figure III.5C and Figure III.6B). 
To verify that GALR2 promotes neuritogenesis, we disrupted GAL-mediated GALR2 
induction. When DRG-UM-SCC-1-GALR2 co-cultures were treated with M871 (a peptide 
41 
 
antagonist against GALR2) or anti-GAL antibody, cancer cell invasion and neuritogenesis 
were inhibited in vitro (Figure III.5D). In the CAM-DRG in vivo PNI model system, M871 
disrupted tumor growth and PNI (Figure III.5E). These findings establish the importance 
of GAL-GALR2 in nerve-tumor interactions. 
 
GAL from Nerve Initiates Nerve-Tumor Crosstalk 
GAL is secreted by both nerves and cancer cells (114, 117), suggesting that nerve-
tumor crosstalk may be initiated by the nerve or cancer. To rule out the possibility that the 
autocrine stimulation of GALR2 by HNSCC-derived GAL is solely responsible for driving 
PNI, we explored the role of neural-derived GAL in promoting invasion. In order to 
investigate this, conditioned medium (CM) from cultured rat DRG was incubated with anti-
GAL or control IgG to deplete GAL (Figure III.7A). Subsequently, the CM was used for in 
vitro invasion assays. UM-SCC-1-GALR2 cell invasion was reduced when GAL was 
depleted compared to CM without depletion (Figure III.7A). These findings show that 
neuronally-derived GAL induces the invasion of HNSCC. HNSCC cells did still invade 
when provided CM with GAL removed, possibly because there is some residual GAL not 
removed by the antibody or because other neutrally-derived proteins also affect tumor 
cell migration.  The amount of residual GAL in the CM could be confirmed by ELISA. 
GAL from nerves induces invasion of HNSCC cells (Figure III.7A) but does not 
induce neurite formation in the same time frame. Since HNSCC also secrete GAL, we 
investigated whether in a feedback loop, GAL released by HNSCC cells induced neurite 
formation. SH-SY5Y cells projected more neurites when incubated with CM from OSCC3-
GALR2 cells compared to CM from control cells (Figure III.6C). In an investigation using 
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DRG explants, CM from both HNSCC-GALR2 cell lines tested induced more 
neuritogenesis than control CM (Figure III.6D and Figure III.7B). Additionally, CM from 
UM-SCC-1-GALR2 cells was used as a chemoattractant to induce SH-SY5Y 
neuritogenesis through a porous membrane. When GAL was depleted in the CM from 
HNSCC cells using the strategy shown in Figure III.7A, fewer neurite projections were 
induced by the CM (Figure III.7C). Taken together, these findings support the hypothesis 
that GAL secreted from DRG and cancer induces invasion and neuritogenesis, 
respectively. 
 
GALR2 Mediates Invasion in HNSCC via NFATC2-Induced COX2 Secretion 
GALR2 activation induces ERK and calcium signalling in cancer and neurons (118), 
leading to their increased proliferation and survival (114, 119). In an independent study, 
increased intracellular calcium and ERK activation leads to the induction and nuclear 
translocation of NFATC2, a transcription factor that induces transcription of pro-
inflammatory cytokines (120). Since GALR2 induces ERK-mediated proliferation (30) we 
investigated its role in activation of NFATC2. NFATC2 expression was higher in multiple 
human HNSCC cell lines compared to normal human oral keratinocytes (Figure III.8A, 
upper blot). In 2 independent HNSCC-GALR2 cell lines, GAL led to nuclear translocation 
of NFATC2 (Figure III.8A, lower blot and Figure III.9A). After testing a panel of 4 
individual siRNAs, si8 was selected due to its superior efficiency in downregulating 
NFATC2 (Figure III.9B). In functional assays, NFATC2 downregulation disrupted 
proliferation (Figure III.8B and Figure III.9C) and invasion (Figure III.8C and Figure 
III.9D). The in vitro findings were validated in vivo using shRNA lentiviral particles to 
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induce the stable downregulation of NFATC2 (Figure III.9E, shNFATC2-2 selected). 
NFATC2 downregulation also decreased HNSCC growth (Figure III.8D) and invasion 
(Figure III.8E) on the CAM. Histology revealed that the basement membrane of the 
surface epithelium was disrupted by multiple invasive tumor islands, whereas siNFATC2 
prevented invasion of the basement membrane (Figure III.8F). Moreover, NFATC2 
knockdown disrupted neural-tumor interactions in vitro and reduced HNSCC invasion into 
DRG (Figure III.8G and Figure III.9F).   
COX2 facilitates the formation of PGE2, a secreted protein important in tumor 
progression. Since NFATC2 induces pro-inflammatory mediators such as COX2 in 
lymphocytes and cancer (121), the promoter regions of Gal (GAL) and Ptgs2 (COX2) 
were interrogated and found to have NFATC2 binding sites. Using chromatin 
immunoprecipitation, we validated that NFATC2 binds the promoter regions of Ptgs2 and 
Gal; binding was higher in UM-SCC-1-GALR2 cells than controls (Figure III.8H).  
Moreover, NFATC2 downregulation reduced COX2 expression (Figure III.9G) and PGE2 
secretion in both HNSCC-GALR2 cell lines (Figure III.8I and Figure III.9H, values 
normalized to rabbit IgG control). Taken together, GALR2 induces PGE2 secretion via 
NFATC2-mediated transcription of COX2. The amount of shRNA-mediated suppression 
of NFATC2 is greater than the total suppression of COX2, likely because we are directly 
targeting NFATc2 using shRNA, however multiple factors, including other NFAT proteins, 
are likely involved in regulating COX2. 
In a meta-analysis of multiple HNSCC datasets, COX2 is upregulated in cancer 
compared to normal (Figure III.10A). COX2 is highly expressed adjacent to nerves in 
most human HNSCC clinical tissue specimens with PNI (Figure III.11A). In mice, 80% of 
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HNSCC-GALR2 tumors expressed COX2 at the invasive front, whereas COX2 was not 
detected in control tumors (Figure III.11B). Immunoblot and ELISA analyses demonstrate 
that HNSCC-GALR2 cells express more COX2 and secrete more PGE2 than controls 
(Figure III.10B and Figure III.11C). HNSCC-GALR2 cells with siRNA-mediated COX2 
knockdown (Figure III.10C, si6 and si8 selected) demonstrated reduced invasion 
compared to controls (Figure III.10D and Figure III.11D).    
 
COX2 Downregulation Disrupts PNI, but not Tumor Neuritogenesis 
COX2 is correlated with PNI in pancreatic cancer (122). Given the importance of 
GALR2-mediated COX2 expression in invasion (Figure III.3), the role of COX2 in 
mediating PNI was investigated. The downregulation of COX2 reduced HNSCC cell 
invasion toward DRG in vitro (Figure III.10E and Figure III.11E). Importantly in vivo, 
siCOX2 inhibited the invasion of HNSCC towards DRG (Figure III.11F, left graph) but did 
not significantly impact neurite growth toward the tumor (Figure III.11F, right graph). 
Together, these studies indicate that COX2 knockdown in HNSCC disrupts HNSCC cell 




In this focused PNI study, nerve-derived GAL initiates crosstalk between nerves and 
cancer cells by activating GALR2 in tumors. In turn, activated GALR2 in HNSCC induces 
NFATC2-mediated secretion of pro-inflammatory mediators and neuropeptides from 
tumor cells, leading to invasion towards nerves and neuritogenesis (Figure III.12).  
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GALR2-mediated PGE2 secretion is required for invasion of HNSCC. Moreover, GALR2-
mediated GAL secretion induces neuritogenesis towards the tumor, thereby completing 
a feedback loop. Targeting GALR2 or GAL disrupts neural-tumor crosstalk, and blocks 
PNI and neuritogenesis. Thus, our findings establish that reciprocal communication 
between nerves and cancer cells occurs during PNI.   
The dynamic interaction between nerves and cancer cells is underexplored. It is 
likely that PNI requires specific biological interactions between HNSCC and nerves since 
HNSCC exhibits a tendency towards neural invasion whereas some other head and neck 
cancers (e.g. low grade mucoepidermoid carcinoma) do not invade nerves (6). Cancer 
cells establish connections with nerves (neural-neoplastic synapse), and are induced by 
neural factors (123) that impact metastasis (124). Nerve-tumor interactions are implicated 
by clinical studies, for example studies showing correlation between PNI and expression 
of nerve growth factor and its receptor, TrkA (25), semaphorin 4D (51) and laminin-5 
(125). Understanding nerve-cancer crosstalk will support the development of targeted 
therapy for PNI.  
Human GAL is a 30-amino acid neuropeptide that regulates memory (126) and has 
neurotrophic and neuroprotective roles (127).  Aside from well-characterized roles of GAL 
in nocioception and regeneration (128-130), GAL is also implicated in non-neuronal 
contexts. For example, GAL is highly expressed in keratinocytes where it may play 
immune and proliferative functions (130), and has abundant binding sites around dermal 
arteries, artiorioles and sweat glands where it may be involved in thermoregulation and 
the immune response (131). GAL has an emerging mitogenic role in cancer (126). For 
example, mice overexpressing GAL develop pituitary tumors (132).  GAL induces 3 G 
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protein-coupled receptors, GALR1, GALR2 and GALR3. While GALR2 and GALR3 are 
pro-proliferative and promote survival (133), GALR1 is a tumor suppressor (114). In 
HNSCC, GAL is anti-proliferative via GALR1, and promotes aggressive tumor growth and 
survival via GALR2 as shown by our previous loss of function studies (30, 114). GALR1 
is frequently deleted or silenced in HNSCC (134, 135), effectively increasing the 
oncogenic activity of GALR2 due to removal of the tumor suppressive activity of GALR1.  
GAL and GALR2 have actions in the neuronal system and in cancer, but possible roles 
in regulating crosstalk between nerves and cancer were previously not investigated.   
Peripheral nerves release molecules that mediate pain and regeneration (136, 137).  
GAL is typically expressed at low levels in peripheral nerves but increases following injury 
(138) and inflammation (139). The CAM model replicates the injury/wound healing 
microenvironment by allowing neovascularization, thereby sustaining the grafted DRG 
and supporting neoneuritogenesis. GAL mediates regeneration and survival of inflamed 
nerves (140). In fact, GAL and GALR2 (but not GALR1) are upregulated in lumbar and 
facial motor neurons after injury (141). Consistent with these studies, we show that the 
GALR2-mediated release of GAL from HNSCC induces neuritogenesis. HNSCC is 
commonly associated with a prominent inflammatory response which may induce nerves 
(142). In a clinical context, encroachment on nerves by an invading tumor, or 
transectioning the nerve while removing a tumor or during a surgical biopsy, may 
stimulate GAL release by nerves, thereby initiating or enhancing nerve-tumor interactions. 
Thus, using a transected nerve on the CAM-PNI model simulates an injured or inflamed 
nerve that is primed to release neuropeptides, resulting in PNI and neuritogenesis. 
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The significance of the primed neural niche in the tumor microenvironment has been 
alluded to through histopathological observation and 3D reconstruction of tumors from 
labeled tissue sections (86). However, the mechanisms of PNI are relatively unknown 
because previously developed in vitro models do not capture the impact of the dynamic 
involvement of the nerve in neural-tumor interactions (7). Most in vivo studies of PNI focus 
on tumor spread and inhibition of motor function, and depend upon direct tumor injection 
into sciatic nerves (87). The sciatic nerve injection model is useful to demonstrate 
destructive tumour progression and pain resulting from tumor cells within nerves. 
However, in bypassing the invasive process and the proliferative or inductive roles of the 
nerve, these previous models do not truly replicate PNI. In a different approach, surgically 
implanted orthotopic tumor grafts in mice were used to characterize the importance of β-
adrenergic receptors in promoting PNI and prostate cancer progression (88). 
The CAM-DRG in vivo model used in our study addresses the deficits of previous in 
vivo models by demonstrating neuronal outgrowth into the peri-tumoral niche. The system 
is also useful in studying therapy to disrupt PNI. The model can be used to evaluate 
response to treatment by measuring the response of the tumor and the nerve, which both 
could promote tumor recurrence. PNI was disrupted chemically with the GALR2 
antagonist M871 or with an antibody to GAL. The GAL depletion method (Figure III.7A) 
allowed us to dissect the specific contributions that nerve-derived GAL contributes to 
invasion and HNSCC-derived GAL contributes to neoneuritogenesis, confirming that 
these processes involve reciprocal interaction between nerves and HNSCC and not just 
the autocrine activation of GAL by the nerve or tumor cells. These studies support that 
therapies targeting GAL and GALR2 should be evaluated as the first potential anti-PNI 
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therapies. Further investigations with this model will elucidate the role of various stromal 
tissues in promoting epithelial-mesenchymal transition, an important phenotype in many 
cancers (79, 143, 144). 
An alternative model could have used xenografted tumors in GAL or GALR2 
knockout mice; however developmental deficits in the neural tissue of these mice make 
this option unfavorable. The nerve is atrophic in GAL-knockout mice (145). In GALR2 
knockout mice, there is a 20% reduction in neurons in the DRG (146), so changes 
observed in HNSCC may not represent alterations in GAL secretion or GALR2 signalling 
but rather an impact on the nerve itself. Since the knockdown of neuronal proteins such 
as GAL or GALR2 causes deficits in mice (145, 147), it was necessary to develop a model 
to evaluate the impact of these proteins on PNI using normal DRG.  
 NFATC2 is emerging as a key regulator of multiple cancer-promoting phenotypes 
(120).  GALR2 and NFATC2 have been independently shown to be important in cancer 
(116, 148), but their mechanism of action is poorly understood. In HNSCC, GALR2 
activates ERK (30) and in adrenal pheochromocytoma cells, GALR2 upregulates 
intracellular calcium (149). Both these effectors stimulate calcineurin, which regulates 
NFATC2. However, prior to this study the role of GALR2 signalling in NFATC2-mediated 
PGE2 secretion was not established. 
A diagnosis of PNI has long been informative to clinicians in treatment planning, but 
the molecular fingerprint and mechanism need to be developed. PNI requires invasion of 
tumor cells through layers of collagen and basement membrane, including the 
epineurium, perineurium and endoneurium, to gain access to axons (7). Factors secreted 
by nerves bind to receptors on cancer cells to facilitate cancer invasion into nerves.  
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Precision medicine is a promising treatment planning strategy that relies upon 
molecular profiling to determine the optimal treatment strategy for each patient. It is critical 
to identify and understand mediators of neural-tumor interactions to include them in these 
molecular profiles. Our study identifies GALR2 as a biomarker and potential treatment 
target of PNI, which may have an implication for future development of personalized 






Figure III.1: GAL predicts clinical outcome in multiple cancer types. A. GAL 
overexpression was correlated with poor clinical outcome in 38 studies across multiple 
cancer types in the OncomineTM database and in recurrent tumors versus primary tumors 
for HNSCC. B. GAL overexpression is significantly correlated with positive lymph node 
status (top graph, from The Cancer Genome Atlas, National Cancer Institute) and 





Figure III.2: GAL correlates with poor survival and neuronal involvement. A. Murine 
tumors with high GALR2, but not control tumors, exhibit PNI (n=3 for both, bar=100µm). 
B. GALR2-expressing murine tumors had more nerves adjacent to the tumors than 
controls (n=3 for both, arrows identify nerves, bar=50µm). C. The Cancer Genome Atlas 
shows that of several neuronal proteins, only GAL expression significantly correlates with 
poor survival (P=0.003, 30th most significant). D. Human HNSCC adjacent to nerves 
expresses GAL (Cytokeratin labels tumor and S100 labels nerves, bar=50µm). *P < 0.05 




Figure III.3: GALR2 promotes tumor invasion and metastasis (UM-SCC-1). A. UM-
SCC-1-GALR2 cells are more invasive than controls when stimulated with GAL (arrows 
label invasive cells, bar=100µm). UM-SCC-1-GALR2 CAM tumors were larger (B, 
bar=500µm), more invasive (C, cancer is green and labeled by arrows, bar=200µm), and 
more destructive of the basement membrane than controls (D, collagen IV and dashed 
lines label basement membrane, bar=100µm). Metastases from the upper CAM to the 
lower CAM were observed (E, cancer is labeled red and shown with arrows, bar=200µm). 
Metastases to the lower CAM and liver were also quantified with qPCR for UM-SCC-1-
GALR2 and control tumors. There were no metastases to the lower CAM or liver in the 
pcDNA; in the GALR2 group 4 eggs had metastases to the lower CAM and 1 had a 
metastasis to the lower CAM and liver (n=6 eggs for both groups). For CAM experiments, 
n=6 for both groups. In vitro data are representative of 3 independent experiments run 




Figure III.4: GALR2 promotes tumor invasion and metastasis (OSCC3). A. OSCC3-
GALR2 cells are more invasive than control cells (OSCC3-pcDNA) when stimulated with 
GAL in the lower chamber of a Boyden chamber assay (bar=100µm).  When seeded on 
a CAM, OSCC3-GALR2 tumors were larger (B, bar=500µm), more invasive (C, cancer 
cells are labeled green, bar=200µm), and more destructive of the basement membrane 
(D, labeled with collagen IV, bar=100µm) than control tumors. For CAM experiments, n=6 
for both groups. In vitro data are representative of 3 independent experiments run with 3 







Figure III.5: GALR2 promotes PNI (UM-SCC-1). A. UM-SCC-1 cells (green) 
overexpressing GALR2 co-mingle with SH-SY5Y neuroblastoma cells (red) and induce 
more neuritogenesis than controls (bar=100µm). B. UM-SSC-1-GALR2 cells are more 
invasive (red arrows) toward DRG than control cells and induce neurite outgrowth (blue 
arrow). C. UM-SCC-1-GALR2 CAM tumors (green) are more invasive and induce DRG 
outgrowth (red, bar=5mm) compared to control tumors. D. UM-SCC-1-GALR2 cell 
invasion (red arrow) and neurite outgrowth (blue arrow) are attenuated with either M871 
(GALR2 peptide antagonist, iGR2) or anti-GAL antibody (iGAL). E. M871 (designated 
iGR2) blocks PNI and downregulates tumor size of UM-SCC-1-GALR2 CAM tumors 
(bar=2mm). Length was quantified in images with ImageJ and expressed in mm or relative 
units (RU). For CAM experiments, n=6 for each group. In vitro and DRG explant data are 
representative of 3 independent experiments run with 3 samples. *P < 0.05 (1-sided t-




Figure III.6: GALR2 promotes PNI (OSCC3). A. OSCC3-GALR2 cells are more invasive 
toward nerves than control cells (red arrows) and induce neurite outgrowth (blue arrows). 
B. On the CAM, OSCC3-GALR2 tumors (green) are more invasive and induce outgrowth 
of nerves (red, identified with arrows, bar=5mm). C. SH-SY5Y neuroblastoma cells 
treated with CM from OSCC3-GALR2 cells differentiated and produce more neurite 
outgrowth compared to control cells. D. Nerves treated with CM from OSCC3-GALR2 
cells generated more neurite outgrowth than nerves treated with CM from control cells. 
For CAM experiments, n=6 for each group, and in vitro and nerve explant data are 
representative of 3 independent experiments run with 3 samples. *P < 0.05 (1-sided t-






Figure III.7: GAL from both the DRG and tumor promote PNI. A. The strategy to 
remove GAL from CM is shown. When CM from DRG is depleted of GAL, it is a less 
effective chemoattractant for UM-SCC-1-GALR2 cells, consequently less invasion is 
observed. B. DRG explants treated with CM from UM-SCC-1-GALR2 cells have more 
neuritogenesis (arrows) than DRG treated with control CM (bar=1mm). C. SH-SY5Y 
neuroblastoma cells extend more neurites (arrows) when treated with CM from UM-SCC-
1-GALR2 cells than when GAL was removed using the strategy shown (A). For all studies 





Figure III.8: GALR2 promotes tumor progression and PNI via NFATC2 (UM-SCC-1). 
(A, upper blot) Multiple HNSCC cell lines express more NFATC2 than normal human oral 
keratinocytes (HOK); (A, lower blot) GAL treatment (5nM) induces nuclear translocation 
of NFATC2 in UM-SCC-1-GALR2 cells. UM-SCC-1-GALR2 cells show reduced 
proliferation (B) and invasion (C) when NFATC2 is downregulated with small interfering 
RNA (siRNA, nontargeting siRNA designated siNT was used for control). UM-SCC-1-
GALR2 CAM tumors with constitutive knockdown of NFATC2 using small hairpin RNA 
(shRNA, control scrambled shRNA is designated “shCtrl” and shRNA targeting NFATC2 
is designated “shNFATC2”) are (D) smaller (bar=5mm), (E) less invasive (arrows show 
invasive islands), and (F) less disruptive of the basement membrane (labeled with 
collagen IV, bar=200µm). (G) UM-SCC-1-GALR2 cells with NFATC2 knockdown exhibit 
less PNI than controls (cancer cells labeled “C” fluoresce green and nerves labeled “N” 
fluoresce red, arrow identifies neurite growth). H. NFATC2 binds more to promoter 
regions of PTGS2 (COX2) and GAL (GAL) in UM-SCC-1-GALR2 cells compared to 
control cells. I. When NFATC2 is downregulated with siRNA in UM-SCC-1-GALR2 cells, 
PGE2 secretion decreases. For CAM experiments, n=6 for both; in vitro and DRG explant 
data are representative of 3 independent experiments run with 3 samples. *P < 0.05 (1-




Figure III.9: GALR2 promotes tumor progression and PNI via NFATC2 (OSCC3). A. 
GAL treatment induces nuclear translocation of NFATC2 in OSCC3-GALR2 cells. B. Four 
individual siRNAs were tested for efficiency in downregulating NFATC2; si7 and si8 were 
selected for functional studies. OSCC3-GALR2 cells exhibit reduced (C) proliferation and 
(D) invasion when NFATC2 is downregulated with siRNA. E. shRNA were tested to use 
for constitutive downregulation of NFATC2 in UM-SCC-1-GALR2 and OSCC3-GALR2 
cells; sh2 was selected. Jurkat cell lysate is a positive control for NFATC2 expression. F. 
OSCC3-GALR2 cells with NFATC2 knockdown exhibit less PNI in vitro than control cells 
(arrow identifies neurite outgrowth in control group). G. COX2 expression is decreased in 
UM-SCC-1-GALR2 and OSCC3-GALR2 cells with constitutive knockdown of NFATC2. 
H. When NFATC2 is downregulated with siRNA in OSCC3-GALR2 cells, PGE2 secretion 
decreases. For CAM experiments, n=6 for both groups. In vitro and DRG explant data are 
representative of 3 independent experiments run with 3 samples. *P < 0.05 (1-sided t-





Figure III.10: COX2 is highly expressed in HNSCC and mediates invasion via 
GALR2. A. A meta-analysis of HNSCC studies on OncomineTM shows that COX2 is highly 
expressed in cancer versus normal samples (P < 0.01).  B. OSCC3-GALR2 cells express 
more COX2 and secrete more PGE2 than control cells (left, immunoblot of whole cell 
lysates; right, ELISA of CM). C. Four individual siRNA were tested in UM-SCC-1-GALR2 
and OSCC3-GALR2 cells; si6 and si8 were selected. Downregulation of COX2 in OSCC3-
GALR2 cells using siRNA decreases invasion on a Boyden chamber assay (D) and also 
decreases invasion of cells toward nerves in co-culture (E). In vitro and nerve explant 
data are representative of 3 independent experiments run with triplicate samples.  *P < 





Figure III.11: COX2 regulates HNSCC progression but not neural-tumor crosstalk. 
A. Most human tumors with PNI express high COX2 adjacent to nerves (arrows, 
bar=100µm). B. Most murine tumors with high GALR2 express COX2 at the invasive front 
(arrows, bar=100µm), but COX2 is not highly expressed by control tumors. C. UM-SCC-
1-GALR2 cells express more COX2 (immunoblot) and secrete more PGE2 (ELISA) than 
controls. D. siRNA-mediated downregulation of COX2 in UM-SCC-1-GALR2 cells 
decreases invasion (arrows label invasive cells, immunoblot verifies knockdown). E. 
Downregulation of COX2 decreases invasion of UM-SCC-1-GALR2 cells toward DRG in 
co-culture. F. siRNA-mediated COX2 downregulation in UM-SCC-1-GALR2 tumors on a 
CAM blocks cancer cell invasion (left graph), but does not affect the extension of DRG 
toward tumors (right graph, bar=100µm). For CAM experiments, n=6 for both, and in vitro 
and DRG explant data are representative of 3 independent experiments run with 3 





Figure III.12: A model of neural-tumor crosstalk mediated by the neuropeptide GAL. 
Neurons release GAL following injury or inflammation and activate tumor-expressed 
GALR2. GALR2 activation leads to NFATC2-mediated transcription and secretion of 





NFATC2 (NFATC2) si7 – GCUUAGAAACGCCGACAUU 
si8 – AGACGGAGCCCACGGAUGA 
si9 – GCAGAAUCGUCUCUUUACA 
si10 – GAACCUCGCCAAUAAUGUC 
sh1  – 5’ TATCTTCTCATAGCTGGTG 3’  
sh2  – 5’ TTTGCTGTCCATCTGTGGT 3’ 
PTGS2 (COX2) si6 – GGACUUAUGGGUAAUGUUA 
si7 – GAUAAUUGAUGGAGAGAUG 
si8 – GUGAAACUCUGGCUAGACA 
si9 – CGAAAUGCAAUUAUGAGUU 
 

























Table III.3: Accession numbers for microarray databases used for meta-analyses. 
  
Database Reference Accession Number 
(150) GenBank Series GSE2379 
(151) GenBank Series GSE13601 
(152) Data referenced in manuscript 
(153) GenBank Series GSE2280 
(154) GenBank Series GSE25099, GSE25103 
(155) GenBank Series GSE20939 
(156) GenBank Series GSE6791 
(157) ArrayExpress E-TABM-302 
(158) ArrayExpress  A-UMCU-3 
(159) GenBank Series  GSE12452 
(160) GenBank Series  GSE3292 
(161) Data referenced in manuscript 
The Cancer Genome Atlas  
(National Cancer Institute) 
Microarray data available through TCGA Data Portal:  
https://tcga-data.nci.nih.gov/tcga/  
(162) GenBank Series  GSE3524 




Table III.4: Meta-analyses of neuronal proteins. Meta-analyses were completed to 
compare expression of 10 neuropeptides and neurotrophins for normal versus HNSCC 
samples using the OncomineTM database. GAL and BDNF were both significantly 
overexpressed in HNSCC. Tachykinin-3 (TAC3), Neurotrophin-4 (NTF4) and Calcitonin-
related polypeptide (CALCB) did not significantly differ in expression in any studies. 
 
  
Full Name (Gene) N (Significant/Non-
Significant Studies) 
t-test (df) P 
Galanin (GAL) 17 (6/11) 2.536 (16) 0.011 
Brain-derived neurotrophic factor 
(BDNF) 
17 (5/12) 2.143 (16) 0.024 
Neural growth factor (NGF) 17 (3/14) 1.327 (16) 0.1015 
Glial cell line-derived neurotrophic 
factor (GDNF) 
13 (2/11) 0.997 (12) 0.169 
Neurotrophin-3 (NTF3) 17 (2/15) 0.84 (16) 0.2065 
Neuropeptide Y (NPY) 17 (2/15) 0.84 (16) 0.2065 
Peptide YY (PYY) 17 (1/16) 0.15 (16) 0.4415 










   
Table III.5: Clinical data. The clinical data associated with human biopsy specimens with 
PNI is provided. 
  
Sex 
   Male 8 
   Female 4 
Age 
   <50 years 1 
   50 years – 70 years 8 
   >70 years 3 
Location(s) 
   Tongue 7 
      Lateral 5 
      Ventral 2 
      Dorsal 1 
      Inferior 1 
   Floor of the mouth 3 
   Buccal mucosa 2 
   Palate 1 
Diagnoses 
   Well differentiated 10 
   Moderately differentiated 1 




The Impact of the Nerve on Metastasis 
 
INTRODUCTION 
Metastasis remains a major problem in cancer treatment and directly contributes 
to 90% of cancer-related deaths (164). Tumors discovered at an early stage can often be 
treated successfully with surgery or irradiation, but after metastasis, treatments are far 
less successful (165). Tumor cells that metastasize not only re-seed at distant sites, but 
can metastasize from the re-seeded tumors to a recurrent tumor at the original site, or to 
additional tertiary sites (166). Therefore, development of novel anti-metastasis treatments 
should be a priority for cancer biologists as these treatments would likely improve the 
survival of patients.  
Epithelial-mesenchymal transition (EMT) contributes to early metastasis of tumor 
cells. Tumor cells that leave the primary tumor must resist anoikis, or apoptosis resulting 
from the loss of cell-cell contact (166). Following this step, also known as detachment, 
metastasizing cells must enter blood vessels (intravasation), survive in circulation, arrest 
in target organ tissue, leave the circulation (extravasation), and  then  seed  at  target  
tissue  to survive and proliferate (164). After invading, cancer cells transition back to an 
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epithelial morphology (mesenchymal-epithelial transition or MET) to proliferate and 
generate metastasized tumors. 
Metastasizing cells face several survival challenges and must cross multiple tissue 
barriers and evade the host immune response (167). Once metastatic cells reach target 
organs, they must regain a blood supply and adapt to a new microenvironment (166). 
Due to the intense survival challenges faced by metastasizing cells, it is believed that only 
a few cells that enter the circulation will actually seed distant metastases (165).  
Over a century ago it was realized that tumor cells do not randomly distribute to 
distant sites throughout the body, but instead favor certain metastatic sites such as the 
liver or lung. Stephan Paget, an English surgeon, observed that the relative blood supply 
was related to the frequency of metastases to these sites. He published the “seed and 
soil” hypothesis in 1889, proposing that metastasis can only occur when the seed, or 
metastatic cell, is compatible to the soil, or target organ of metastasis (168).   
This hypothesis follows that in order for the outgrowth of a tumor, the tumor must 
get compatible growth signals from the microenvironment (166). Also, cooperation 
between the normal host tissue and tumor cells is essential in order for cancer to survive 
the perilous survival challenges faced in the process of metastasis (164). There is a 
growing appreciation in the cancer biology community of host-tumor interactions involved 
in temporal and spatial regulation of metastasis. Early investigations of host-tumor 
interactions in the early metastatic niche have identified endothelial cells, platelets and 
leukocytes as some of the host partners regulating metastasis (164). 
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PNI has been correlated with metastasis in many clinical studies of head and neck 
squamous cell carcinoma (HNSCC) (6, 169-171). Although host nerves in the tumor 
microenvironment may play a role in regulating metastasis, the mechanism of this 
interaction is unknown. An in vivo model that can capture the dynamic interaction between 
tumor and nerves with an option of quantifying metastases is necessary to understand 
the role of nerves in metastasis. In this chapter, we propose a CAM-based model to 
evaluate nerve-tumor interactions in the context of metastasis. Knowledge of nerve-tumor 
interactions in the context of metastasis may contribute to development of therapies 
targeting early metastasis.   
 
METHODS 
Cell Culture. HNSCC cell line UM-SCC-1 (from Thomas Carey, University of Michigan) 
was genotyped to verify the cell line at the University of Michigan DNA Sequencing Core 
prior to studies. Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, 
Gibco®) supplemented with 10% fetal bovine serum (FBS, Gibco®) and 1% PenStrep 
(Gibco®). Cells were transfected with pcDNATM3.1-GALR2 (Missouri S&T cDNA 
Resource Center). 
 
Data Analysis. GraphPad Prism (GraphPad software) was used for statistics. Student’s 




 CAM Model. Fertilized Lohmann White Leghorn eggs were obtained from the Michigan 
State University Department of Animal Sciences Poultry Farm. The eggs were incubated 
and randomly distributed into treatment groups of 6-8 eggs, and tumor cells were seeded 
as described (66). Chick embryos that did not develop or eggs that became contaminated 
during the experiment were excluded from analysis.  
 
CAM Nerve-Tumor Metastasis Assay. DRG were dissected from rats within 1 hour of 
euthanasia and labeled using CellTracker Red CMTPX (InvitrogenTM). DRGs were 
seeded on the CAM with fluorescently-labeled HNSCC cells dyed with a lipophilic tracer, 
DiO (a dialkylcarbocyanine derivative). The CAM was harvested after 3-6 days. A 1 cm2 
portion of the upper CAM was collected from the window used to seed the cells. The shell 
was cut in half horizontally and a 1 cm2 portion of the lower CAM was collected from the 
portion of the CAM directly below the tumor, from an area containing a density of 
vasculature. The middle portion of the liver was also collected for analysis. Tumor area 
was imaged using a Leica Stereo microscope and quantified using ImageJ.  Additionally, 
lower CAM tissue was imaged using a Leica Stereo microscope to observe metastatic 
tumor nodules, and lower CAM and liver tissues were digested and human DNA 









Overview of the CAM Nerve-Tumor Metastasis Model 
 Figure IV.1 shows a flowchart of the CAM nerve-tumor metastasis model. Briefly, 
a fertilized chicken egg is opened, and a rat dorsal root ganglion (DRG) is placed on the 
upper CAM. Subsequently, human HNSCC cells are seeded on the CAM, and the system 
is incubated for 2-6 days, depending on interest in early or late metastatic events. After 
incubation, the upper CAM is harvested for imaging and histological analysis. The lower 
CAM and liver of the developing chick are also collected for qualitative and quantitative 
analysis of metastases. The lower CAM can be imaged to view metastatic tumors, and 
both the tissue from the lower CAM and liver are digested and human DNA is quantified.  
 
Nerves Contribute to Increased Tumor Size 
 We performed a time course experiment to investigate the impact of the nerve on 
tumor growth. Using the approach outlined in Figure IV.1, we seeded tumor cells alone 
or co-grafted a nerve and tumor on a CAM, and collected the upper CAM from the eggs 
at days 13, 14 and 15 of development. Stereo microscopy images of the tumors are 
shown in Figure IV.2A. The area of the tumors was quantified for each day of the 
timecourse and compared. Although the tumors with or without nerves did not differ in 
size at the initiation of the timecourse, by day 15 the tumors with nerves were significantly 




Nerves Contribute to Increased Tumor Metastases 
After determining that the nerve enhances tumor size, we investigated the impact 
of the nerve on metastasis of the tumors. If a nerve enhances metastasis, it may do so 
by enhancing tumor cell proliferation or survival. Therefore, we evaluated metastasis at 
day 13, a timepoint before there was a difference in tumor size between tumors with and 
without nerve. The lower CAM was imaged using a Stereo microscope, and metastatic 
tumor nodules were observed embedded in lacey vascular structure in tumors seeded 
with nerve. However, tumors seeded without nerve did not have obvious metastases 
(Figure IV.3A). Additionally, the lower CAM tissues were digested and human DNA 
quantified. There were about 2.5 times as many metastatic tumor cells present in lower 
CAM tissue from tumors seeded with nerves compared to tumors without nerves (Figure 
IV.3B). We also attempted to quantify DNA in tissues from livers of the chick embryos but 
we did not see a difference in metastatic cells between the 2 groups. This is likely in part 
because liver metastases would be a later metastatic event in this system, which would 
require additional days of incubation, and also because at such an early timepoint the 
livers of the chicks are underdeveloped and may not support metastases.   
 
DISCUSSION 
Using the CAM nerve-tumor metastasis system, we were able to confirm that the 
interaction of nerves with tumor contributed to the growth and metastatic potential of 
HNSCC tumors. This system allows us to both quantitatively and qualitatively observe 
interactions of nerves with tumors and the resulting metastatic tumors to the lower CAM 
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of the chick eggs. Several advantages, as well some limitations of the model are listed in 
Table IV.1. 
In vivo model systems of metastases generally fall into 2 groups: xenograft 
transplantable models, which like our model, contain tissues from different species, and 
syngeneic models, which include tissues from the same species or carcinogen-induced 
or spontaneous tumors (166). Our system is a xenograft system since it contains tissues 
from human, rat and chicken species. Syngeneic models are useful since they can be 
adapted to an immunocompetent animal, however due to inbreeding, tumors lack the 
genetic complexity usually observed in human tumors. In contrast, xenograft tumors can 
be readily adapted to include human cells, but must use immunodeficient animals which 
limits the ability to observe the role of the immune system in tumor progression (166).   
Using either a xenograft or syngeneic transplantable model approach, the next 
choice when developing a model is to use an experimental metastasis system (where 
tumors are injected directly into the circulatory system, such as in a lateral tail vein 
injection), or a spontaneous metastasis system. Experimental metastasis models are 
rapid, and tight control over the entry point of cells into the circulation has led to some 
valuable observations of the metastatic process (172). However, with experimental 
metastasis models, the initial steps of invasion are bypassed and therefore the location 
of the resulting metastatic tumors may depend mostly on the blood circulation from the 
site of the injection. For example, metastases from a lateral tail vein injection develop in 
the lung, whereas metastases from a portal vein injection develop in the liver. Ultimately 
however, artificial injection of tumor cells does not replicate true metastasis; tumors may 
be inadvertently seeded into the circulation system, or alternatively the mechanical 
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disruption of host tissue may actually suppress metastasis (173). Spontaneous 
metastasis models may be harder to control and more time consuming, however the initial 
steps of invasion are preserved, which can lead to different mechanisms of metastases 
produced through experimental and spontaneous systems, such as differences in 
expression of matrix metalloproteinases, which are essential for invasion (174).   
The CAM tumor-nerve metastasis model described depends on spontaneous 
metastasis, and therefore the early invasive events are preserved. Spontaneous 
metastasis models may involve orthotopic seeding of tumor cells (for example injection 
of HNSCC tumor cells into the oral mucosa, a site at which the primary tumor occurs), or 
heterotopic seeding, or seeding of tumor cells at a site different from the origin of the 
tumor. For example, subcutaneous injection of HNSCC cells onto the backs of mice is 
heterotopic seeding. The seed-soil hypothesis correctly predicts that tumors are more 
suitably supported at the site of origin (i.e. a site containing the correct soil to support a 
particular type of tumor), and therefore more metastases are generally seen from tumors 
seeded at orthotopic sites than heterotrophic sites (166).   
The CAM system does not have oral mucosa, and therefore orthotopic seeding of 
HNSCC tumors is not possible. However, we carefully selected the CAM model for our 
metastasis system because of the distinct similarities between the CAM and oral mucosa, 
including a basement membrane and rich blood supply seen in both types of tissue. We 
have observed that HNSCC cells readily grow and metastasize in the CAM system, 
thereby suggesting that the CAM mimics several important characteristics of oral mucosa. 
Tumor size and angiogenesis are readily quantified within the first 2 days after the tumor 
cells are seeded.  Invasion is observed by 2 days post-seeding, and metastasis is 
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observed within 3-10 days. The process of tumor growth, invasion and metastasis is 
similar to the sequence of clinical progression of HNSCC, and replicates the progression 
from early non-invasive pre-cancerous lesions to invasive lesions that breach the 
basement membrane. An important difference between the CAM and oral mucosa is that 
the CAM does not have a rich supply of nerves. This is a great benefit to our CAM-nerve 
model since the impact of neural tissue on tumor progression can be evaluated by 
addition of DRG. Due to the simplicity of the CAM structure, it may be possible to adapt 
this model to study the importance of other stromal elements in host-tumor interactions 
regulating metastasis. 
While the initial steps of metastasis including intravasation and arrest may only 
take a few minutes, the later steps may take hours or days to complete (164). Due to the 
short timeframe of early metastatic steps, these steps have been historically overlooked 
as potential therapeutic targets, and the focus of therapy has been on controlling the bulk 
of the tumor. EMT cells and stem cells likely evade tumor cytolytic therapies, and 
therefore therapies that target invasion and metastasis are essential to improve patient 
outcomes (164). Anti-metastatic therapies will be useful to prevent metastases for 
patients presenting with tumors that have a high likelihood of metastasis, and to prevent 
re-seeding of tumors at primary sites (recurrence) from metastases at tertiary sites (175).  
In order to develop effective anti-metastatic therapies, we must develop a greater 
understanding of specific host-tumor interactions contributing to metastasis. Our CAM 
nerve-tumor model can be adapted to observe interactions of multiple host tissues within 
tumors. Also, it is possible to use pharmaceuticals in the CAM model system to attempt 
to disrupt mechanisms of metastasis. In the future, we intend to use this model to further 
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investigate the mechanism by which tumor-nerve interactions promote metastasis and 
PNI. Also, we are using the CAM nerve-tumor model to develop a mathematical model of 





Figure IV.1: A timeline showing the CAM-PNI cancer progression model. A rat DRG 
and human HNSCC cells are co-grafted onto a fertilized chicken egg, and then incubated. 
After several days, the upper CAM is collected and imaged, and the lower CAM and liver 






Figure IV.2: Time course of HNSCC tumors grown in absence or presence of a 
nerve. HNSCC tumors grown in presence of absence of a nerve (A, arrows highlight frank 
PNI that becomes increasingly apparent through over the 3 timepoints). B. By day 15, 




Figure IV.3: Metastases quantified in presence or absence of nerve. A. Metastatic 
nodules noted in lower CAM tissue (arrow) for tumor grown in presence of a nerve. B. 
When human DNA in lower CAM tissue is quantified with qPCR, tumors grown in the 
presence of a nerve have significantly more metastatic cells in lower CAM tissue than 




 Short time duration 
 Can observe metastasis 
qualitatively and quantitatively 
 Can use human cells 
 Can adapt to study interactions with 
other types of tissues 
 Can observe metastases across 
many timepoints, including very 
early timepoints 
 Can use pharmacological agents 
 Inexpensive, can use with large 
sample number 
 Can adapt to in vivo microscopy 
techniques 
 Lack of immune interactions 
 Host tissue differs genetically 
from human tissue 
 Limited by development of 
immune system in developing 
chicken 
 Technically demanding 
 




Conclusion and Future Directions 
Conclusion 
Invasion is the critical phenotype of tumor progression that distinguishes pre-
cancer from HNSCC. Understanding the molecular mediators of invasion will lead to 
diagnostic and prognostic biomarkers and potential novel treatment targets. EMT and 
tumor-stromal interactions contributing to invasion are areas of increasing interest in 
cancer biology. Nerve-tumor interactions contribute to aggressive tumor progression, 
however the mediators of these interactions are poorly understood due to the lack of 
appropriate research models. In this thesis, we present in vitro and novel in vivo methods 
to investigate invasion and specifically, PNI. Using our CAM-based in vivo approach, we 
demonstrate that nerve-derived GAL initiates crosstalk between nerves and cancer cells 
by activating GALR2 in tumors. Activated GALR2 then induces NFATC2-mediated 
secretion of pro-inflammatory mediators and neuropeptides from tumor cells, leading to 
invasion towards nerves and neuritogenesis. We demonstrate that GALR2-mediated 
PGE2 secretion is required for invasion, and GALR2-mediated GAL secretion induces 
neurite outgrowth towards the tumor, thereby completing a feedback loop. Our findings 
clearly establish that reciprocal communication between nerves and cancer cells occurs   
during PNI (Figure V.1). Our model is the first in vivo approach that allows reciprocal 
interaction of tumor and nerve.  Additionally,  we  adapt  the CAM-PNI model to study the 
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impact of the nerve on growth and metastasis of HNSCC. Our studies show that the 
presence of a nerve in the microenvironment of developing HNSCC promotes aggressive 
tumor growth and metastasis.   
 
Future Directions 
 Our data indicate that GAL and GALR2 may be viable anti-PNI treatment targets.  
We show that blocking GAL by using an antibody, or GALR2 by using the protein 
antagonist M871, block PNI and tumor neuritogenesis. Furthermore, blocking NFATC2 in 
GALR2-overexpressing HNSCC cells also inhibits PNI in vitro and in vivo. In the future, 
we will also investigate the impact of Tacrolimus on HNSCC in vitro and in vivo. 
Tacrolimus is a macrolide immunosuppressant that prevents the dephosphorylation or 
activation of NFATC2. Tacrolimus and similar macrolides that inhibit NFAT activation 
have been used extensively in clinic to treat several diseases including oral lichen planus, 
vitiligo and atopic dermatitis (177). Additional in vivo validation using these potential anti-
PNI therapies is necessary to determine if they may be useful therapeutically in HNSCC.   
In addition, it is important to further explore the mechanism of neuron-tumor 
crosstalk, and especially to understand the soluble mediators of these interactions that 
are expressed by both the nerve and the tumor. It has been shown that soluble factors 
secreted by nerves can induce tumor cell migration (136). We hypothesized that 
neuronally-derived GAL initiates PNI by activating GALR2 on tumor cells. Our data 
support this hypothesis; if GAL is removed from conditioned medium from nerves, 
invasion of HNSCC cells is downregulated. Further investigation of how the concentration 
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gradient of neuropeptides affects the interaction between cancer and nerves, which 
respond to the same neuropeptides, will facilitate our understanding of PNI. The 
development of a nerve-specific GAL inducible conditional knockout mouse, or HNSCC 
cell lines with inducible knockout of GAL will facilitate these studies.  
 Our work highlights the importance of the G protein-coupled receptor (GPCR), 
GALR2, in promoting PNI and tumor-neuron crosstalk. GPCRs have been implicated as 
potential treatment targets of tumor-neuron interactions (137, 178). GPCRs are often 
overexpressed in a variety of cancer cells and the ligands of GPCRs regulate several 
phenotypes, including proliferation, migration and survival, of both cancer and nerves 
(178). Importantly, GPCRs play a role in promoting and maintaining a microenvironment 
that favors tumor growth (179). GPCRs and their ligands may mediate a neural-tumor 
synapse that leads to active cross-talk between the 2 tissue types, facilitating growth and 
survival of nerves and HNSCC, as well as cancer-associated pain. Although mutations of 
GPCRs have not been specifically linked to PNI, it is possible that future investigations of 
tumor-driving GPCR mutations will reveal their importance in promoting tumor-neuronal 
crosstalk and PNI. 
Given the grave clinical significance of PNI, it is essential to highlight the 
importance of nerve-tumor interactions in promoting aggressive tumors to the clinical 
community. Our hope is that our work highlighting PNI will eventually lead to a prognostic 
model that will encourage clinicians to adopt more rigorous and standardized methods to 
identify and treat PNI appropriately. Histopathologic detection of PNI is very challenging 
due to the complex microanatomy of peripheral nerves, particularly with subtle 
microscopic presentations (12). Currently used terminology to describe PNI is confusing; 
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there is a lack of standardization of definitions and quantification schemes to describe 
PNI, which can lead to delayed recognition of PNI and mistreatment. The terms small 
nerve or incidental, and large nerve or clinical PNI are used interchangeably but carry 
different prognostic significances (6). In the absence of staining for neuronal markers, 
pathologic detection of PNI may be missed at tumor margins and in tangential sections 
of nerves. Shortfalls in clinical detection, reporting and researching PNI have resulted in 
a gap of understanding of this deadly pathologic process. Ultimately due to our lack of 
understanding of the disease, anti-PNI therapeutics have not been developed. When PNI 
is detected, clinicians often opt for aggressive adjuvant therapies for lesions that may be 
treated more effectively and conservatively with anti-PNI therapy. Ultimately improved 
understanding of the molecular biology of PNI, including markers of perineural 
involvement in genetic profiling of tumors, will assist clinicians and scientists in the effort 
to develop and adapt personalized medicine strategies to treat patients. 
The general future directions of this work are to develop methodology in detecting, 
reporting and researching PNI. We intend for our work to address specific deficiencies in 
clinical and basic science research that are holding back progress in this important 
research area. This will accelerate development of life-saving treatment protocols that 
effectively manage tumors that exhibit PNI. A diagnosis of PNI has long been informative 
to clinicians in treatment planning, but the molecular fingerprint and mechanism must be 
elucidated. Personalized medicine is a promising treatment planning strategy that relies 
upon molecular profiling to determine the optimal treatment strategy for each patient 
(Appendix E). PNI mechanisms have not been determined previously, and therefore 
there are no prognostic markers of PNI (6). Since PNI is known to be associated with 
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aggressive tumors, it is critical to identify and understand molecular mediators of neural-
tumor interactions to include them in these molecular profiles.  






















Biomarkers of Epithelial-Mesenchymal Transition in Squamous Cell Carcinoma 
Appendix A is adapted from a published manuscript (79). 
 
Introduction 
Understanding the process by which tumor cells destroy the basement membrane 
of the surface epithelium, invade and metastasize is essential to developing novel 
treatment of HNSCC. In recent years, there has been increased interest in the role of 
epithelial-mesenchymal transition (EMT) in facilitating invasion. EMT describes the 
development of motile cells from non-motile parent epithelial cells (Figure A.1). EMT, 
which occurs in embryonic development, wound healing, and cancer (Figure A.2), is 
classified into 3 subtypes (180). Type 1 occurs in gastrulation and in migration of neural 
crest cells; some of the migrated cells undergo mesenchymal to epithelial transition (MET) 
to become epithelial cells in organs produced by the mesoderm and endoderm. This 
embryological EMT occurs in the orofacial region during palatogenesis. Type 2 occurs in 
wound healing and can result in fibrosis when there is persistent inflammation. Cytokines 
generated by tissue injury induce the fibroblast phenotype from epithelial or endothelial 
cells. Type 3 occurs in subsets of invasive cancer cells by using some of the Type 2 EMT 
program for migration and aggregation of epithelial cells in wound healing. After invading, 
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tumor cells can transition back to the epithelial morphology (MET) to proliferate and 
generate tumors at distant sites.  
The purpose of this chapter is to present the growing evidence that EMT has a 
significant role in invasion and metastasis of HNSCC. Many protein types, including cell-
surface proteins, cytoskeletal proteins, extracellular matrix (ECM) components and 
transcription factors contribute to EMT (Figure A.3, Table A.1).   
 
CELL-SURFACE PROTEINS 
Cell-surface proteins contributing to EMT in HNSCC include cadherins and integrins. 
Cadherins 
E-cadherin is the main protein of adherens junctions that anchor oral epithelial cells 
to each other. It is a calcium-dependent cell surface protein that facilitates adhesion 
between epithelial cells. E-cadherin is characterized by long cytoplasmic and extracellular 
domains, which create homophilic interactions between adjacent cells to facilitate 
adhesion. The expression of E-cadherin is decreased during embryonic development, 
tumor fibrosis and cancer progression (180). In oral epithelial cells, from which HNSCC 
develops, surface E-cadherin anchors cells to each other and links to the cytoskeleton 
via -catenin. Loss of or sequestration of E-cadherin in the nucleus impairs cell-cell 
adhesion and releases -catenin, which translocates to the nucleus to induce 
transcription of EMT genes, such as TWIST.  
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Several studies show reduced E-cadherin in HNSCC, with lowest E-cadherin levels 
in poorly differentiated tumors (181). E-cadherin expression is similar between primary 
tumors and metastases, perhaps due to MET in metastatic tumors. The promoter region 
of the E-cadherin gene (CDH1) is hypermethylated in HNSCC, but hypermethylation is 
not correlated with advanced stage (182), mortality or second primary tumor (183).  Meta-
analysis of E-cadherin studies in HNSCC showed that abnormal E-cadherin expression 
is predictive of diminished disease-specific survival (184).  
The use of E-cadherin expression to personalize anti-HNSCC therapy has been 
explored (185, 186). Higher E-cadherin expression is correlated with better sensitivity 
toward the EGFR-tyrosine kinase inhibitors. The E-cadherin to N-cadherin switch, which 
occurs during embryonic development and cancer progression, is used to monitor EMT.  
E-cadherin is expressed in epithelial cells, and N-cadherin is upregulated by TWIST in 
type 3 EMT in gastric cancer (187). In HNSCC, high expression of N-cadherin correlated 
with malignant behaviors such as high grade pattern of invasion and poorly differentiated 
cancer cells (188). Cadherin switching (high expression of N-cadherin and low expression 
of E-cadherin) was observed in 30 of the 80 cases and correlated with invasion and lymph 
node metastasis, as well as EMT features. Thus, cadherin switching may be a critical 
event in the progression of HNSCC through EMT.  
 
Integrins 
EMT facilitates relocation of cells from above the basement membrane into the ECM, 
which involves a change in expression of integrins (180). Integrins are heterodimeric 
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adhesion receptors composed of α and β subunits. There are 18 α and 8 β subunits that 
variably combine into 24 different integrins.  Integrins bind to ligands, including collagens, 
laminins, and fibronectin in the ECM. Ligand-bound integrins induce several signaling 
cascades that control cell polarity, motility, survival, shape, proliferation and 
differentiation.   
Integrins mediate interactions between cells and the surrounding ECM by making 
transmembrane connections between the cytoskeleton and the ECM. The interaction 
between the α5 integrin and fibronectin is necessary for metastasis of a melanoma cell 
line (189). Blocking the α5 subunit in HNSCC, decreases adhesion to collagen IV and 
fibronectin (190). α5β1 integrin has been associated with cisplatin resistance and 
enhanced adhesion to fibronectin, which is abolished when the integrin is blocked by a 
neutralizing antibody (191). β1 integrin increases invasion of HNSCC cells, which 
decreases significantly when the integrin is blocked (192). 
 
CYTOSKELETAL MARKERS 
Cytoskeletal proteins that contribute to EMT in HNSCC include alpha-smooth muscle 
actin (α-SMA), vimentin and β-catenin. 
 
α-SMA 
Cells expressing α-SMA contribute to EMT in embryogenesis and wound healing in 
normal epithelial cells (180). In squamous cell carcinoma (SCC), the tumor tissue is 
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surrounded by reactive stroma, made up mostly of cancer associated fibroblasts (CAFs), 
also known as myofibroblasts because they acquire characteristics of muscle fibers, 
including expression of α-SMA. Expression of α-SMA is controlled by growth factors and 
specialized ECM proteins. α-SMA is incorporated into stress fibers of fibroblasts thereby 
augmenting their contractile ability, which is critical to tissue remodeling. CAFs are known 
to potentiate the development and progression of epithelial cancers. Fibroblasts can be 
distinguished based on the stage of tumor development by differences in α-SMA 
expression, which is expressed more highly in mature fibroblasts than newly transitioning 
cells. Fibroblasts from HNSCC tumors grow more slowly compared to normal fibroblasts 
from the oral cavity (193).   
HNSCC characterized by extensive genetic copy number alterations, loss of 
heterozygosity and inactivation of p53 and p16INK4A had higher α-SMA expression, 
which correlated with poor prognosis in an independent dataset of HNSCC samples when 
compared with tumors with less genetic instability (193). However, the mechanistic link 
between α-SMA expression and EMT and HNSCC is unknown. 
 
Vimentin 
Vimentin is an intermediate filament that is used as a marker of mesenchymal cells 
to distinguish them from epithelial cells (180). Vimentin is expressed at sites of cellular 
elongation and is associated with a migratory phenotype. Increased vimentin expression 
is frequently used as an EMT marker in cancer.   
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In HNSCC cell lines, Chen et al. isolated an ALDH1-rich subpopulation of cells and 
characterized their invasive potential and EMT phenotype (194). Spheroid-derived cells 
had increased vimentin when compared to monolayer-derived cells from different cell 
lines. Furthermore, vimentin expression decreased when cells were grown as a 
monolayer. Vimentin expression is higher in nodal metastatic cells than in the primary 
HNSCC tumors, and is enhanced by epidermal growth factor and TGF-β (195). Reducing 
vimentin levels by RNA-interference decreased the proliferation, migration and invasion 
of metastatic cells compared to control cells (195). Yoon et al. developed an orthotopic 
model of HNSCC metastasis and selected HNSCC cells through 4 rounds of serial 
metastasis to obtain a highly metastatic subpopulation (196). The metastatic population 
acquired mesenchymal features including increased vimentin and integrin α1 and 
reduced epithelial expression, including reduced E-cadherin and involucrin. In contrast, 
non-metastatic parental cells had low vimentin expression. 
 
β-Catenin 
The Wnt/β-catenin pathway has a critical role in invasion in HNSCC (197). E-cadherin 
is anchored to the cytoskeleton via -catenin, a cytoplasmic plaque protein (198). In loss 
of cell adhesion, as occurs in invasion, E-cadherin is endocytosed and -catenin is 
released. In normal and non-invasive cells, β-catenin is usually localized to cell 
membranes. In cells undergoing EMT, β-catenin is located in the cytoplasm (reflective of 
its dissociation from E-cadherin). This cytosolic (free) -catenin translocates to the 
nucleus to promote transcription of genes that induce EMT. Nuclear β-catenin is a 
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transcriptional co-activator with T cell factor (TCF)/Lymphoid enhancer-binding factor 
(LEF), which controls transcription of SNAIL1 (180).   
Nuclear β-catenin is correlated with a poor prognosis in patients with metastasic 
HNSCC (199). Rap1, a ras-like protein, stabilized β-catenin and increased its nuclear 
localization; more advanced N-stage lesions were associated with high free β-catenin and 
high active Rap1 (197). 
 
ECM PROTEINS 
The ECM proteins that promote EMT in HNSCC include collagen, fibronectin and 
laminin. 
Collagens 
While migration of normal cells is strictly controlled by limited proteolysis of the ECM, 
in cancer, proteolytic remodeling of the ECM facilitates invasion (200). Collagens are the 
major structural components of the ECM. There are 28 types of collagen that have a triple 
helical structure. Collagen I and II are fibrillary collagens, while collagen IV constitutes a 
sheet-like structure that is the major component of basement membranes. There is 
increased expression of collagen I (α1) and collagen III (α1) in type 1 and 3 EMT, while 
collagen IV (α1) is down-regulated in all 3 types of EMT (180). 
Collagen type I is the most prevalent form in the interstitial matrix. In HNSCC, 
collagen type I RNA transcripts are more widely expressed in HNSCC than in pre-
cancerous or normal tissue. Collagen I stimulated cytokine secretion in genetically 
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matched primary and metastatic HNSCC cell lines, but cytokine secretion was 
significantly upregulated in metastatic cells when seated on collagen I (α1) gel (192). The 
cytokines released (IL-1α, IL-1β, IL-6, TNF-α and TNF-β) stimulated MMP activity and 
invasion of the HNSCC cells. IL-6 is overexpressed in HNSCC and is a biomarker of poor 
disease-specific survival (201). Moreover, collagen I enhanced MMP-2 and MMP-9 
secretion in both the primary and metastatic cell lines (192). MMP-9 is a biomarker that 
contributes to invasion of HNSCC and is correlated with poor disease-specific survival 
(202). 
Collagen III (α1) is an ECM component that promotes cancer progression in ovarian 
(203) and breast cancers (204).  In HNSCC, collagen III (α1) cDNA was found to be highly 
expressed in a Paclitaxel-resistant cell line (205). Altered collagen IV (α1) was linked to 
invasion and motility of cancer cells. Laminin in tumor cells binds collagen IV (α1) and 
then secretes gelatinases that break down collagen IV (α1) to facilitate migration of tumor 
cells (180). Surprisingly, Chen et al. found that collagen IV RNA is increased in HNSCC 
surgical specimens compared to dysplastic and normal tissues (206). Further 
investigation is necessary to determine the role of collagen IV in invasion of HNSCC. 
 
Fibronectin 
Fibronectin is a glycoprotein scaffold for fibrillar ECM (180). It is composed of a dimer 
of similar subunits of repetitive sequences covalently linked by 2 disulfide bonds at their 
C-termini. In normal cells, fibronectin mediates cellular interactions with the ECM and is 
important in migration, differentiation, growth and adhesion of cells. Although fibronectin 
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is up-regulated in all 3 types of EMT, its use as an EMT biomarker is limited because it is 
produced by many cell types such as epithelial cells, fibroblasts and mononuclear cells, 
(187). Fibronectin can be up-regulated by SNAIL and TWIST in type 3 EMT. 
In HNSCC, there are contradictory reports with respect to expression of fibronectin.  
Dooley et al. showed that fibronectin and its receptor are strongly upregulated with α5β6 
integrin in SCC cell lines and tissues (207). Three fibronectin isoforms (extra domain A, 
extra domain B, and IIICS) are generated via alternative splicing depending on cytokine 
and pH conditions. Fibronectin fragment ED-B is not expressed in normal tissues (except 
those undergoing wound healing) but expression is correlated with HNSCC and tumor 
cell aggressiveness (208). The ED-A and IIICS isoforms are expressed in blood plasma 
of HNSCC patients, suggesting that hydrolytic enzyme-aided invasion leads to 
degradation of EMC components (209). 
 
Laminin 
Similar to collagen, laminin is a major component of the basement membrane.  
Laminins are glycoproteins made up of one α chain, one β chain and one γ chain. There 
are 15 known heterotrimers of laminin. Laminin 1 (α1β1γ1) is the laminin of greatest 
interest in EMT types I and II, where it is downregulated or disrupted. Laminin 5 (α3β3γ2) 
has been linked to EMT in metaplastic carcinoma of the breast and hepatocarcinoma 
(180). 
The role of laminin 5 in HNSCC is clearly significant. Laminin 5 has been shown to 
be a major component of the ECM, and laminin 5 expression correlated with invasion and 
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patient prognosis. Interestingly, the laminin 332 G4 domain, a proteolytic product of 
laminin 5, promotes laminin 5 deposition, and may have a role in wound healing and SCC 
formation (210). In a study comparing HNSCC, pre-cancer and normal tissues, 
overexpression of transcripts of LAMC2 encoding laminin-γ2 chain and COL4A1 collagen 
IV α1, distinguished HNSCC from pre-cancerous and normal tissues that had lower 
LAMC2 (206). In another study, high LAMC2 predicted poor HNSCC-specific survival 
(211).   
 
TRANSCRIPTION FACTORS 




SNAIL proteins regulate various aspects of the EMT phenotype, including 
overexpression of mesenchymal markers fibronectin and vitronectin, and suppression of 
epithelial markers, including E-cadherin, (180). In addition, SNAIL blocks cell cycle 
progression and contributes to cell movement and survival. Other targets of SNAIL 
proteins, include genes regulating cell polarity and apoptosis. SNAIL family proteins are 
evolutionarily conserved in vertebrates where they have a conserved role in embryonic 
mesoderm formation.   
98 
 
There are 3 transcription factors in the SNAIL family, of which SNAIL1 and SNAIL2 
are functionally equivalent (180). SNAIL1 is important in mediating invasion and 
inflammation through transcriptional regulation of cytokines, and also in preventing 
terminal differentiation of HNSCC cells (212). EMT phenotypes and invasion in HNSCC 
are reduced with siRNA-mediated knockdown of SNAIL1 (213). SNAIL1 expression in 
primary tumors of HNSCC patients is correlated with metastasis and poor prognosis.  
SNAIL1 expression correlates with histopathologic grade and depth of invasion in HNSCC 
(214) and is correlated with poor differentiation of the tumors, lymphovascular invasion 
and regional metastasis (215). Knockdown of SNAIL1 in HNSCC cell lines attenuated 
cisplatin resistance by facilitating DNA excision repair by stabilizing ERCC1, which is 
necessary for nucleotide excision repair (216). Lysyl Oxidase–Like 2, a marker of poor 
prognosis in SCC, regulates EMT in part by stabilizing SNAIL1 to facilitate tumor 
progression (217).  
Hypoxia contributes to tumor metastasis by initiating EMT through activation of 
SNAIL2 in HNSCC. SNAIL2 is critical for the induction of MT4-MMP in a hypoxic 
environment (218). Overall, there is strong evidence to suggest that SNAIL proteins play 
a role in EMT in HNSCC. 
 
TWIST 
TWIST is a basic helix-loop-helix protein that modulates many target genes through 
E-box responsive elements.  There are 2 TWIST genes (TWIST1 and TWIST2) which are 
well-conserved in vertebrates. TWIST is activated in all 3 types of EMT and is up-
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regulated in cancer metastases (180). While mesoderm formation is controlled by SNAIL 
family proteins, TWIST1 is important in mesoderm differentiation. TWIST proteins can 
either act as transcriptional repressors (e.g. E-cadherin) or activators (e.g. N-cadherin 
and fibronectin). 
In HNSCC, TWIST expression is positively correlated with lymph node metastasis 
and clinical stage (219). Hypoxia-inducible factor-1α (HIF-1α) promotes EMT and 
metastatic phenotypes in HNSCC via upregulation of TWIST expression. Repression of 
TWIST reverses the EMT and metastatic phenotypes. BMI1, a polycomb-group protein 
frequently overexpressed in cancers, is regulated by TWIST in HNSCC (220). BMI1 and 
TWIST expression lead to down-regulation of E-cadherin, which is associated with poor 
prognosis (220). In a study of 109 HNSCC patients, negative SNAIL1 and TWIST 




LEF-1, a cotranscriptional activator with TCF, mediates WNT signaling. Through this 
regulation, LEF-1 plays a role in deciding the fate of cells in normal embryonic 
development (180). In EMT, the β-catenin/LEF-1 complex is localized to the nucleus 
where it controls SNAIL gene expression, along with other markers associated with EMT.  
LEF-1 functions with β-catenin to promote cell survival and proliferation during mammary 
gland development and in breast cancer (222). LEF-1 and β-catenin are upregulated and 




In addition to proteins that have a role in HNSCC progression or a correlation with 
HNSCC, there are several potential biomarkers that should be explored in HNSCC.  
These proteins have been shown to have a role in EMT in other cancers, but to our 
knowledge have not been investigated in HNSCC. 
Forkhead box protein c2 (FOXC2) is a transcription factor that is expressed in type I 
EMT and is important in angiogenesis, musculogenesis and the development of the heart, 
kidney and urinary tract. FOXC2 is expressed in ductal breast cancers and metastatic 
breast cancer (180). Overexpression of EMT transcription factors such as SNAIL and 
TWIST increase FOXC2 expression. Furthermore, the overexpression of FOXC2 can 
induce EMT, which suggests that FOXC2 may play a role in type 3 EMT.  
Expression of zona-occludens 1 (ZO-1) occurs in all 3 types of EMT (180). ZO-1 is a 
tight junction protein that is usually located at cell-cell adhesion membrane complexes in 
normal epithelial cells. During EMT, ZO-1 relocates from the adhesion membrane 
complexes to the cytoplasm and then to the nucleus, depending on the degree of 
differentiation and migration of the cell (224). ZO-1 is involved in the EMT process in 
colorectal and bile duct cancers, but has not yet been linked to EMT in HNSCC (225, 
226).  
Zinc finger E-box binding homeobox 1 (ZEB1) is an E-cadherin transcriptional 
repressor that is downregulated by miR-200 microRNAs in cancer cells that display an 
EMT phenotype (180). ZEB1 has been investigated in prostate cancer, non-small cell 
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lung carcinoma and invasive ductal breast cancer, but has not been investigated in 
HNSCC (227-229). 
Osteoblast cadherin (OB-cadherin) is a definitive marker for activated fibroblasts 
(180). While in cancer and embryonic development, an E-cadherin to N-cadherin switch 
is used to monitor EMT progression, an E-cadherin to OB-cadherin switch may indicate 
EMT progression in type II EMT specifically. In cancer, OB-cadherin has an association 
with prostate and breast cancer where it is hypothesized to be involved in metastasis; its 
expression in HNSCC is unknown (230).    
Cancer stem cells (CSC) are a small population of tumor cells that can both initiate a 
tumor and repopulate a tumor following treatment, contributing to treatment resistance.  
In HNSCC, a sub-population of CD44+ cancer stem cells display a phenotypic switch to 
become either proliferative or migratory (231). The migratory population, designated 
CD44highESAlow, displays reduced E-cadherin and increased vimentin, TWIST, SNAIL1 
and SNAIL2, features of EMT cells. Given the striking similarities between EMT and this 
subpopulation of CSCs, it is likely that future research will elucidate the role of EMT in 
maintaining the CSC population.  
EMT progression involves many signaling pathways that may be targeted in the 
clinical setting (232, 233).  Figure A.4 summarizes some of the pathways and anti-EMT 
therapies. The mechanistic role of the EMT markers associated with HNSCC should be 
clearly defined in order to develop new anti-HNSCC therapies to block HNSCC 
progression. Understanding the role of EMT in HNSCC will allow clinicians to personalize 
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Figure A.1: EMT to MET. Epithelial-like cells display tight cell-cell contacts and maintain 
polarity, whereas mesenchymal-like cells are more motile and display more contact with 
the extracellular matrix. Proteins associated with the epithelial-like or the mesenchymal-
like states are referred to as biomarkers. As cell progress through EMT and MET, the 
levels of proteins associated with each state are altered, reflecting the phenotypic switch 




Figure A.2: Three types of EMT. Type 1 EMT occurs in development, for example when 
in gastrulation epithelial cells transition to motile mesenchymal cells. Type 2 EMT occurs 
when secondary epithelial or endothelial cells move to interstitial spaces in wound healing 
or chronic inflammation resulting in fibrosis. Type 3 EMT occurs when epithelial tumor 




Figure A.3: Proteins involved in EMT. Several proteins have been identified as 
biomarkers of EMT. These proteins include cell surface proteins, cytoskeletal proteins, 





Figure A.4. Targeted therapies against EMT pathways. EMT progression involves 
many signaling pathways that may be targeted in the clinical setting, which include 




Biomarker Category Proteins References 
Cell Surface Proteins E-Cadherin (231) 
N-Cadherin (188) 
Integrins (190) (191) (234) 
Cytoskeletal Proteins α-SMA (193) 
Vimentin (196) (195) (194)  
β-catenin (235) (199) (197)  
Extracellular 
Matrix Proteins 
Collagen (I) (206) (234) 
Collagen (III) (204) (203) 
Collagen (IV) (206) 
Fibronectin (207) (208) (209)  
Laminin 5 (210) (206) (211)  
Transcription Factors SNAIL1 (213) (212) (214) (216) (215)  
SNAIL2 (218) 
TWIST (219)  
LEF-1 (223)  
 




CDH11 is a Novel Biomarker of EMT in HNSCC: Discovery and Validation Using 
an In Silico Approach 
Appendix B is adapted from a manuscript that has been submitted for review (236). 
 
INTRODUCTION 
Analyses of existing datasets have long informed investigation of potential 
oncogenes or tumor suppressor genes. Preliminary studies of datasets in the existing 
literature assisted researchers in designing focused and cost-effective studies.  
Translational researchers have been especially empowered by clinical datasets.  
However, previously the availability of datasets to researchers was limited by access to 
journals and the lack of effective search tools.  In recent years, these limitations have 
been lifted as an increasing number of datasets have become available to researchers 
through multiple online databases.   
The availability of datasets has changed the practice of oncology research, 
enabling powerful statistical studies that are both used in preliminary searches for 
molecules to study, and to supplement benchtop studies (237). Modern databases of 
research outcomes have reinforced the value of statistics in biology (238).  The enormous 
increase    in   available  information  has   launched   the   rapidly   developing   field   of 
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bioinformatics, which focuses on the assembly and utilization of biological databases.   
The growth of bioinformatics reflects the increasing importance of statistics in biological 
science, shifting the value of quantitative results over qualitative results.   
Easily navigable and increasingly comprehensive in silico studies using databases 
can suggest whether a gene is involved in a clinical outcome of interest and even hint at 
possible mechanisms. These databases comprise a new genre of in silico investigation 
(237). In silico analyses are becoming an increasingly popular mechanism to identify 
novel molecular targets for study. Moreover, translational researchers use in silico 
analyses linked to clinical data to complement results generated in the laboratory. Meta-
analyses of existing micro-array data demonstrate correlations of markers across many 
cancer types and clinical conditions. 
As in silico analysis becomes a standard of translational research studies, more 
databases are being assembled for bioinformatics analysis. Available databases include 
corporate for-fee databases, university-constructed compilations of research outcomes 
and clinical data, and government-run databases from several countries.  Many examples 
of databases containing data of interest to oncologic researchers are listed and described 
in Table B.1. The Cancer Genome Atlas (TCGA) is an extensive database managed by 
the National Cancer Institute and the National Human Genome Research Institute that 
links DNA copy-number variations with multiple cancer types and clinical parameters 
(239). The database used in the present study is the OncomineTM database, which 
currently brings together information from 699 datasets. Studies collected into 
OncomineTM report over-expression and under-expression of genes across many studies 
that include a range of cancer types and sub-types (239).   
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In this study we demonstrate the value of in silico experiments to nominate and 
investigate markers of epithelial to mesenchymal transition (EMT) in head and neck 
squamous cell carcinoma (HNSCC). EMT is a process by which non-motile epithelial cells 
become motile, and occurs normally in embryonic development and wound healing (180).  
EMT can also promote invasion and metastasis in cancer (240). Understanding the 
mechanism of EMT in HNSCC will advance our understanding of tumor progression (79).  
HNSCC has maintains a dismal 40-50% 5-year survival rate due to lack of effective novel 
treatment strategies (1).  Biomarkers involved in EMT may be attractive treatment targets 
for HNSCC, and potentially leading to novel personalized medicine strategies. Our results 
show that multiple EMT markers are highly expressed in HNSCC and correlated with poor 
clinical outcome, altered sensitivity to chemotherapy and multiple oncogene mutations.  
In addition, we use in silico analyses to reveal strong correlations between CDH11 
(osteoblast-cadherin) and poor clinical outcomes in HNSCC. CDH11 is an emerging EMT 
marker that is thought to have a role in wound healing and breast cancer progression but 
little is known about the role of CDH11 in HNSCC (230). CDH11 has been shown to be 
variably expressed in oral cancer tissues with qPCR (241). Additionally, CDH11 DNA is 
found to be differentially methylated between primary and metastatic oral tumors (242).  




In silico studies. The Oncomine database (Oncomine™, Compendia Bioscience, Ann 
Arbor, MI) was used for in silico experiments. Eighteen head and neck cancer datasets 
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were identified using the search parameters “Cancer Type: Head and neck cancer” and 
“Analysis Type: Cancer vs Normal Analysis”. Datasets from studies of adenoid cystic 
carcinoma, thyroid carcinomas or pharyngeal carcinomas were excluded. The following 
studies were retained: Cromer Head- Neck (150), Estilo Head-Neck (151), Ginos Head-
Neck (152), Kuriakose Head-Neck (243), Peng Head-Neck and Peng Head-Neck 2 (154), 
Pyeon Multi-cancer (156), Talbot Lung (161), Toruner Head-Neck (162), TCGA Head-
Neck, Ye Head-Neck (244). Overexpression of EMT markers in HNSCC was 
demonstrated in multiple datasets. Several filters were used to generate heat maps with 
corresponding statistical analyses correlating expression of EMT markers with different 
clinical outcomes, drug responses and oncogene mutations. In addition, a summary of 
CDH11 overexpression in multiple cancer types was generated, and genes coexpressed 
with CDH11 in HNSCC were identified. 
 
Statistical Analysis. GraphPad Prism® was used for statistical analyses. HNSCC 
datasets with mRNA expression data (n=9) were identified in Oncomine. Meta-analyses 
were performed as described (245). Expression of EMT markers was compared between 
normal and HNSCC samples by Student’s t-test in each HNSCC dataset, and a P-value 
<0.05 was determined to be statistically significant. Each statistically significant study was 
given an arbitrary value of “1” and non-significant studies were designated a value of “0”.  
A one-sample t-test was performed for each set of values, with a target value of 0.05, and 




Immunohistochemistry. Immunostaining was performed on formalin-fixed, paraffin-
embedded HNSCC tissue and cell lines, as described (246). The CDH11 affinity purified 
rabbit polyclonal antibody was from R&D Systems, and rabbit IgG (Dako) was used as a 
negative control at the same concentration as the primary antibody.  
 
RESULTS 
HNSCC Datasets Provide Extensive Data for in silico Studies 
 The Oncomine database contained 699 datasets and 80915 samples at the time 
of this study.  Of the available datasets, 36 were identified as “Head and Neck Cancer” 
datasets. Figure B.1 gives an overview of the content of these datasets.  DNA or mRNA 
expression data is available for the datasets (Figure B.1A). While most datasets contain 
less than 75 samples, 11% contain more than 151 samples (Figure B.1B). The data 
provided comes from a range of sources, including cell panels, tissue panels and TCGA, 
which was compiled by the National Cancer Institute and National Human Genome 
Research Institute (Figure B.1C). The specimens used to generate the datasets include 
surgical specimens and samples collected by laser-capture microdissection, manual 
microdissection and macrodissection (Figure B.1D). Several available filters for head and 
neck cancer dataset analyses are listed in Table B1. Expression levels of biomarkers 
analyzed in the datasets can be linked to many interesting parameters listed including 
sample site, clinical outcomes, molecular subtypes, pathological subtypes, drug 




EMT Biomarkers are Overexpressed in HNSCC 
 A summary of representative histograms detailing expression levels in the 
individual studies used to compile the meta-analyses are shown in Figure B2.  
Overexpression of multiple EMT markers in HNSCC is shown, along with a meta-analysis 
of the expression level in cancer versus normal for the markers across several datasets 
(Figure B3). SNAI2, TGFB1 and CDH11 are significantly overexpressed in HNSCC 
across 9 datasets. 
 
EMT Biomarkers are Correlated with Aggressive HNSCC 
 Dataset filters were used to correlate EMT biomarker expression with different 
HNSCC clinical parameters using the TCGA Head-Neck dataset containing DNA copy-
number data. SNAI2 was significantly overexpressed in tumors with positive nodal status 
(Figure B.4A, P = 0.030). CDH11 and ACTA2 were both correlated with metastasis 
(Figure B.4B, P = 1.82 x 10-5 and P = 0.004, respectively). CDH11 was also significantly 
correlated with death at 5 years (Figure B.4C, P = 0.02). 
 
CDH11 is Expressed in HNSCC Cell Lines and Tissue 
 In silico data suggested that CDH11 is overexpressed in HNSCC, and expression 
levels correlate with more aggressive tumors. In order to validate our in silico findings, we 
investigated the expression of CDH11 in HNSCC cell lines and tissues. Using 
immunohistochemistry, we found that CDH11 is variably expressed across non-malignant 
and malignant oral epithelial cell lines (Figure B5). HOK16B is a transformed human 
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keratinocyte cell line, which shows low expression of CDH11 compared to HNSCC cell 
lines.  We validated the antibody for immunohistochemistry on paraffin-embedded tissues 
using colon cancer tissue and associated tumor stroma, which are known to express 
CDH11 (247).  After finding that CDH11 appropriately stained our positive control tissues, 
we immunostained normal human oral mucosa and pre-neoplastic (epithelial dysplasia) 
tissues. CDH11 was expressed at low levels in normal human oral tissue (Figure B.6A). 
Next, we immunostained a tissue microarray (TMA) containing human HNSCC tissues 
and normal oral tissues. CDH11 had low expression in normal tissue, but was variably 
expressed across HNSCC samples (Figure B.6B). HNSCC samples exhibited both 
higher intensity of staining, and also a higher proportion of cells were stained when 
compared to normal tissues on the TMA (Figure B.6B). These data confirm that CDH11 
is expressed in HNSCC tissues at higher levels than normal tissue.  
 
DISCUSSION 
 Translational researchers are faced with the challenge of making relevant 
correlations between clinical problems and experimental studies. In silico investigations 
using multiple datasets provide researchers a practical approach to enhance benchtop 
investigations with clinically-oriented data or to discover potential new biomarkers.  In the 
present study, we performed meta-analyses of multiple datasets to evaluate expression 
of EMT markers. Expression of some EMT markers was correlated with common 
oncogenic mutations.  We were able to correlate overexpression of EMT biomarkers with 
multiple clinical parameters, emphasizing the role of EMT in HNSCC progression. 
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 We identified EMT markers that were differentially associated with sensitivity to a 
variety of therapeutics.  HNSCC has been challenging to treat due to lack of effective 
novel therapies, and the next era of HNSCC treatment will focus on personalized 
medicine (248). In silico studies of datasets provide insight into which biomarkers could 
be used to select the best therapy for patients on a case-by-case basis. 
 Although in silico studies based on expression of genes are useful, they do not 
identify all proteins important to tumor progression, specifically those regulated post-
translationally. In silico experiments may suggest novel biomarkers, but validation of 
expression in tissues and cell lines is essential. Since microarrays investigate thousands 
of genes, false positives are inevitable at any practical P-value. We identified CDH11 as 
a new EMT biomarker in HNSCC in multiple in silico analyses. We then verified that 
CDH11 is expressed in HNSCC via immunoblot and immunohistochemistry. In contrast, 
expression of proteins that are activated or inactivated by phosphorylation, such as the 
tumor suppressor tristetraprolin (TTP), is not as informative as the phosphorylation status 
of the protein (105). 
A molecular concept map may associate expression of a protein with a phenotype 
of interest, such as cancer recurrence. For example, a molecular concept map revealed 
that the Myc pathway is associated with breast cancer relapse (249). Pathway analysis 
is an additional method of analysis that models molecular pathways. Noting gene 
expression levels along the stages of cancer progression can reveal the mechanism of 
progression and prognosis associated with pathway activation (250, 251). In addition to 
gene expression databases, databases of information from electronic health records have 
been examined in aggregate to identify linkages between health problems. Studies 
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demonstrating the link between non-insulin-dependent diabetes mellitus with retinopathy 
and hypertension or the unexpected link between pyloric stenosis and ventricular septal 
defects demonstrate the utility of bioinformatics even with standard clinical data (252).  
This technique can be applied to clinical records of cancer patients to potentially identify 
links between cancer and other health factors or conditions.   
The wide range of available databases reflects the rising importance of in silico 
analyses. These analyses represent an approach to obtain additional, in-depth and up-
to-date data on a gene and its function without the additional expense of benchtop 
studies. As studies are incorporated into readily accessible databases, the application of 
bioinformatics techniques will become increasingly useful. Furthermore, textual analysis 
techniques are making it practical to analyze large-scale sets of medical records thereby 
putting volumes of clinical records into a searchable format. Useful correlations, trends 
and risk factors can be queried and characterized. Given the value of in silico studies and 
the improving quality and availability of datasets, the use of bioinformatics techniques 
may become a standard expectation of any review of clinically relevant biomarkers and 




Figure B.1: Details of Head-Neck cancer datasets. A. A larger number of datasets 
provide mRNA expression (78%) levels than DNA copy-number analyses (22%). B. While 
most of the sample sets have less than 75 samples (61%), 11% contain more than 151 
samples. C. Data are supplied by a range of sources including cell and tissue and data 
from sources including The Cancer Genome Atlas (TCGA), which is compiled by the 
National Cancer Institute and National Human Genome Research Institute. D. Samples 
represent a variety of sources, including cell lines, surgical specimens, and both macro 





Figure B.2: Expression of EMT biomarkers. Representative histograms for studies of 
the expression levels of the following EMT biomarkers are shown: ACTA2 (Ginos, P = 
2.48 x 10-6; Peng, P = 0.001; Toruner, P = 0.150; and Ye, P = 0.002); CDH11 (Cromer, P 
= 0.004; Estilo, P = 6.91 x 10-5; Ginos, P = 3.86 x 10-17; Toruner, P = 0.002); SNAI2 (Estilo, 
P = 2.40 x 10-10; Ginos, P = 7.92 x 10-11; Peng, P = 5.04 x 10-11; Toruner, P =  0.018); 
GFB1 (Cromer, P = 0.045; Estilo, P = 3.14 x 10-6; Ginos, P = 1.52 x 10-4; Peng, P = 5.09 




Figure B.3: Overexpression of EMT biomarkers in HNSCC. Overexpression of EMT 
biomarkers was determined among 9 studies: 1) Cromer Head-Neck (150), 2) Estilo 
Head-Neck (151), 3) Ginos Head-Neck (152), 4) Kuriakose Head-Neck (243), 5) Peng 
Head-Neck (154), 6) Pyeon Head-Neck (156), 7) Talbot Lung (161), 8) Toruner Head-
Neck (162), 9) Ye Head-Neck (244). SNAI2, TGFB1 and CDH11 were all significantly 
overexpressed (P = 5.04 x 10-11, P = 0.045, and P = 3.17 x 10-4, respectively). Greater 
red intensity indicates a lower (more significant) P-value for comparative overexpression 




Figure B.4: SNAI2, CDH11 and ACTA2 are correlated with aggressive HNSCC. DNA 
copy-number of a panel of EMT biomarkers was correlated with HNSCC clinical 
parameters. A. SNAI2 was significantly overexpressed in tumors with positive nodal 
status (P = 0.030). B. CDH11 and ACTA2 were both correlated with metastasis (P = 1.82 
x 10-5 and P = 0.004, respectively). C. CDH11 was also significantly correlated with death 





Figure B.5: Validation of CDH11 expression across HNSCC cell lines. CDH11 is 
variably expressed across several HNSCC cell lines as observed by 
immunohistochemical detection. HOK16B is a transformed human keratinocyte line that 
exhibits low staining of CDH11. HNSCC cell lines were incubated with an anti-CDH11 
antibody followed by an anti-rabbit secondary antibody. Immunostained cells were 







Figure B.6: Validation of CDH11 Expression in HNSCC tumors. A. Normal oral 
mucosa exhibit low staining of CDH11 in the cytoplasm and some staining in the nucleus. 
B. On a tissue microarray, normal tissue exhibits low staining of CDH11, and CDH11 is 
variably expressed across HNSCC tissues. When quantified, HNSCC tissues stained with 
significantly higher intensity, and a higher proportion of each sample stained when 
compared to normal oral tissue.  
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Characterization of Squamous Cell Carcinoma in an Organotypic Culture via Sub-
surface Nonlinear Optical Molecular Imaging 
Appendix C is adapted from a published manuscript (70). 
 
INTRODUCTION 
 Head and neck cancer is the sixth most common cancer globally, affecting about 
600,000 individuals per year (1). Over 90% of these lesions are HNSCC. New treatments 
are required since current regimens have not improved survival in over 5 decades. Due 
to the complexity of the many structures and tissues involved in HNSCC progression, 
researchers struggle to accurately replicate the disease process in an in vitro setting. 
Development of models that more closely simulate human HNSCC will enhance 
translation of pre-clinical studies into successful novel targeted therapies.   
 Invasion of transformed epithelial cells beyond the basement membrane and into 
the connective tissue is the defining event that differentiates pre-cancerous oral lesions 
from HNSCC. The basement membrane separates epithelial cells from the underlying 
connective tissue and is identified histologically by expression of collagen IV (5). 
Destruction  of  the  basement  membrane  and invasion with subsequent regional spread  
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and distant metastases contribute to the lethality of HNSCC. Since invasion is the key 
event of tumor progression, a sophisticated model that replicates the basement 
membrane and connective tissue stroma is necessary to study invasion in HNSCC and 
many other cancers.   
 To address the limitations of existing in vitro models of invasion, our laboratory 
developed the Oral Cancer Equivalent (OCE) model using human HNSCC cells and 
human connective tissue. Recent advances in tissue engineering have provided 
xenografts or autologous grafts for humans based on stratification of keratinocytes on 
human decellularized cadaveric dermis (253). To facilitate studies on the invasive 
phenotype of HNSCC, we adapted the procedure for creating normal oral tissue grafts to 
generate the OCE. In the adapted protocol, decellularized human dermal tissue is coated 
with collagen IV and seeded with human HNSCC cells, which are allowed to stratify and 
invade. This novel in vitro model simulates invasion of human HNSCC including the 
complexity of connective tissue and the histopathology. Figure C.1A shows a HNSCC 
lesion that presented as a leukoplakia (white patch) on the lateral surface of the tongue.  
Figure C.1B shows a similar “clinical” appearance of the OCE construct. In both Figure 
C.1C and Figure C.1D, arrows indicate invading cells and arrowheads highlight the 
location of the basement membrane on tissue sections of a HNSCC tumor and an OCE 
construct. The pattern of rete ridge formation and islands of invasive cells in HNSCC 
(Figure C.1C) are closely simulated by invasion of HNSCC cells in the connective tissue 
stroma of the OCE (Figure C.1D).   
 In a recent publication describing the role of the RNA binding protein tristetraprolin 
(TTP) in HNSCC progression, our lab used the OCE model to quantify HNSCC invasion 
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(105). The OCE method allowed us to quantitatively compare invasion of cells with short-
hairpin RNA-mediated knockdown of TTP (shTTP) with control cells (treated with 
scrambled shRNA, shSCR) on fixed tissue sections. Our initial data showed that cells 
with TTP-knockdown were more invasive than control cells. The analysis in our previous 
study was limited to quantification of invasive cells in fixed tissue sections at a single 
timepoint.  
 In the present study, we demonstrate the feasibility of using nonlinear optical 
molecular imaging to image sub-surface live cells on the OCE constructs. With this 
method, green fluorescent protein (GFP)-tagged cells are used for the OCE constructs, 
and invasion can be traced at multiple timepoints and at multiple locations on the 
constructs. In addition, decay of the collagen matrix by the cancer cells can be quantified 
through obtaining a second harmonic generation (SHG) signal from the connective tissue 
matrix. We used shTTP-treated cells that we previously showed to be more invasive 
compared to shSCR-treated control cells to validate and optimize the novel imaging 
method presented in this manuscript (105). We also compared our live cell imaging 
results with histological data of fixed tissue sections at multiple time points. Overall, sub-
surface nonlinear optical molecular imaging of the OCE confirmed histological 
quantification of invasion of fixed tissue sections from OCE constructs. The live cell 
imaging method provided additional levels of analysis by providing a 3D view of cells 
interacting with the connective tissue matrix in addition to quantification of collagen decay 





Overview of the OCE Method. The overview of the OCE protocol is shown (Figure 
C.2). Circular fragments of decellularized human dermis were hydrated and coated with 
human collagen IV. Cells expressing green fluorescent protein (GFP) were seeded on the 
tissue and allowed to stratify over several days. Invasion of cancer cells and decay of 
connective tissue matrix were observed and quantified using sub-surface nonlinear 
optical microscopic molecular imaging over 2 days, after which the constructs were fixed 
for histopathological studies.   
 
Cell Culture. The HNSCC cell line UM-SCC-1 (from T. Carey) was used for these studies.  
HNSCC cells were transduced with short hairpin RNA (shRNA) constructs with a vesicular 
stomatitis virus glycoprotein (VSVG) backbone and a GFP tag in lentiviral particles.  A 
scrambled shRNA (designated shVSVG) was used for the control and shTTP was used 
for TTP knockdown (Open Biosystems, Catalog No. RHS4430-99139230, Sequence 
5’TATTAGAATAAATAAAGTC 3’).  UM-SCC-1 cells (35 x 104) were transduced with 1000 
multiplicity of infection of control and TTP knockdown vectors in serum-free medium for 3 
hours prior to adding 10% FBS.  Puromycin (10 ug/ml) was used to establish stable cell 
lines over 4 weeks.  Protein knockdown was confirmed by immunoblot analysis.  
 
Preparation of Human Dermal Tissue. Decellularized dermal tissue (AlloDerm®, 
LifeCell Corporation) was cut into disks that fit into the individual wells of a 48-well plate.  
Dermal tissue was placed in a 100 mm cell culture dish and rehydrated with 15 mL 
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Dulbecco's phosphate-buffered saline (DPBS, Invitrogen), which was changed every 15 
minutes for 90 minutes. Forceps were used to aseptically remove the dermal tissue from 
its commercial packaging. The tissue was gently rinsed with DPBS to determine 
orientation of the tissue (DPBS added to the epidermal side with the basement membrane 
easily drains off of the tissue, whereas DPBS added to the dermal side is retained). The 
dermal tissue was transferred, epidermal side facing up, into a well of the 48-well 
microplate. The tissue was gently pressed into the microwell plate to ensure there were 
no bubbles beneath the tissue. One hundred microliters of DPBS was added to each of 
the wells with tissue. Five microliters of human collagen IV (Fluka, 5 µg/μl suspended in 
acetic acid) was added to the middle of the DPBS covering the dermal tissue. Human 
collagen IV was added to enhance HNSCC cell attachment to the decellularized dermal 
tissue (254, 255). The plate was sealed with Parafilm (BioExpress) and refrigerated 
overnight at 4°C.   
 
Seeding and Cultivating Cancer Cells on Hydrated Dermal Tissue (day 0). UM-SCC-
1 cells transduced with shVSVG or shTTP were grown to 60% confluence. The 48-well 
microplate containing hydrated dermal tissue coated with collagen IV was warmed in a 
cell culture incubator (37°C, 5% CO2) for 30 minutes. Five hundred microliters of complete 
Dulbecco's Modified Eagle Medium (DMEM) culture media containing 10% fetal bovine 
serum (FBS) and 1% PenStrep (10,000 Units/mL Penicillin and 10,000 µg/mL 
Streptomycin) was added to the wells of the 48-well microplate containing the prepared 
dermal tissue. The complete media provided the nutrients for the HNSCC cells.  The 
HNSCC cells were seeded onto dermal tissue at a density of 5 x 105 cells in 100 µl of 
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DMEM.  Cells were incubated in a cell culture incubator at 37°C and 5% CO2 for 4 days, 
and the medium was changed every 2 days.  
 
Transfering the OCE to the Air-Liquid Interface (day 5). Transwell carrier inserts (3.0 
µm pore size, Costar, Corning Inc.) were placed in a 6-well cell culture dish, and 500 µL 
of complete DMEM culture medium with 10% FBS and 1% PenStrep was pipetted below 
the insert.  Using sterile forceps, the OCE constructs were lifted by the edge of the dermal 
tissue and transferred with the epidermal side facing up onto one of the inserts. The 
constructs were incubated at 37°C in a 5% CO2 incubator for 2-3 days, and the medium 
in the lower chamber was changed every day.  
 
Nonlinear Optical Microscopic Molecular Imaging (days 7 and 8) 
Instrumentation and Data Acquisition. Nonlinear optical microscopic molecular 
imaging was performed on a Leica TCS SP5 microscope in epi-illumination mode. The 
images were collected with a 25x water immersion objective lens (0.95 NA, 2.5 mm 
working distance). A tunable Ti:sapphire laser (Mai Tai, Spectra-Physics), providing 
excitation wavelengths ranging from 690 to 1040 nm, was employed to deliver 100 fs 
pulses with a 80 MHz repetition rate. A 900 nm excitation wavelength was employed to 
simultaneously excite GFP fluorescence and collagen SHG. For GFP detection, the 
emitted fluorescence was coupled through a band pass filter from 475 to 575 nm, and 
collected with a non-descanned photomultiplier tube positioned in close proximity to the 
sample to increase collection efficiency. For SHG detection, an internal tunable 
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photomultiplier was tuned with a narrow bandwidth, 440-460 nm, to selectively collect 
collagen SHG emission. En-face images were acquired with raster scanning in the lateral 
plane and cross-sectional images were acquired with line scanning in the transverse 
plane. The scanning speed was 200 lines per second, for a total image acquisition time 
of approximately 40 seconds for the entire field-of-view. To reduce background noise, 
each line was acquired 8 times, and averaged. The microscope, laser, and image capture 
were under computer control. 
 
Specimen Preparation. OCE specimens were placed on a glass-bottom 35 mm Petri 
dish, and wet with a few drops of DPBS to preserve cell viability during the imaging 
procedure. The Petri dish was placed on the microscope, and en-face images were taken 
at incremental z-steps of either 3 µm, 5 µm, or 10 µm at 4 sites of the TTP-knockdown 
assay, and 3 sites of the control assay. Vertical cross-section images were taken at 1 site 
for each of the TTP-knockdown constructs and for the control OCE. All measurements 
were made in less than 1 hour after removing specimens from incubation conditions.  
 
Image Analysis. Two-photon excited fluorescence images of GFP-expressing cells and 
SHG images of collagen from the Alloderm® scaffold were pseudo-colored green and 




Data Analysis. Cell invasion was assessed by using MATLAB software to analyze z-
stack en-face SHG channel images to count the number of pixels with intensity values 
above a certain threshold over the entire field-of-view. The intensity threshold, 𝐼𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑, 
is defined to be 𝐼𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 =  𝜇𝑅𝑂𝐼, where 𝜇𝑅𝑂𝐼 is the mean of the intensity of all non-zero 
pixels in the region of interest. A decreased number of SHG pixels exceeding the 
threshold indicated the presence of cancer cells decaying the collagen matrix at the given 
depth below the surface, which was then plotted as a function of depth to assess cell 
decay of the collagen matrix by the cancer cells. The mean of the pixel counts was 
calculated over each en-face image of 3 TTP-knockdown assays and 2 control assays, 
both imaged on day 8 post-seeding, with error bars of one standard deviation of the mean. 
 
Histopathological Studies. OCE constructs were fixed overnight in phosphate buffered 
formalin (Fisher Scientific). Hematoxylin and eosin staining was performed on tissue 
sections prepared from fixed OCE constructs, and invasive areas were identified.   
 
RESULTS 
Enhanced Invasion of HNSCC Cells with TTP Knockdown is Observed with Both Sub-
surface Imaging and Analysis of Fixed Samples 
 Pro-inflammatory mediators, including cytokines and matrix metalloproteinases, 
contribute to progression of HNSCC (197, 202, 256). TTP is an RNA-binding protein that 
induces decay of multiple pro-inflammatory mediators (257). We previously showed that 
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downregulation of TTP leads to increased production of pro-inflammatory mediators and 
increased invasion of cancer cells (201). In data presented, HNSCC cells were stably 
transduced with a short-hairpin RNA (shRNA) construct to downregulate TTP (shTTP) 
and a control construct (shVSVG). These cells were used to investigate the sub-surface 
nonlinear optical molecular imaging method to monitor invasion on the OCE constructs 
and compare the results to parallel histopathological analysis. 
 HNSCC cells stratified to 2-4 layers, similarly to normal keratinocytes, and 
developed rete ridges (Figure C.1D). Invasive islands beyond the basement membrane 
were observed on hematoxylin and eosin-stained tissue sections. The increased invasion 
of cells with downregulated TTP was visualized by hematoxylin and eosin staining of 
paraffin embedded tissues (Figure C.3) and cross-sectional nonlinear optical microscopic 
molecular imaging of live cells.  Control cells formed a generally uniform layer that sits on 
the OCE scaffold (Figure C.3A), whereas TTP-knockdown cells invaded below the OCE 
scaffold, forming nests of GFP-expressing cells beneath the surface of the OCE (Figure  
C.3B, arrowheads).   
 Two-photon excited fluorescence images of GFP-expressing cells and SHG 
images of collagen from the OCE scaffold were pseudo-colored green and blue, 
respectively, and then merged in 8-bit RGB color format using NIH Image J software. 
GFP channel images taken near the surface of the assay show a high number of cells in 
cell lines with or without downregulation of TTP. At 24 μm control cells are no longer 
visible while TTP-knockdown cells are still visualized, suggesting increased deeper 
invasion of the TTP-knockdown cells below the surface of the OCE scaffold. A montage 
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of en-face images of the TTP-knockdown OCE from depth 0 μm to 24 μm revealed islands 
of GFP-expressing cells invading below the specimen surface, visualized as circular rings 
apparent deep under the surface of the OCE up to 24 µm (Figure C.4).    
 
Enhanced Invasion and Basement Membrane Destruction by HNSCC Cells with TTP 
Knockdown is Quantified with Sub-surface Imaging 
 Nonlinear optical microscopic en-face images of control and TTP-knockdown 
assays, imaged on day 7 post-seeding, are shown (Figure C.5A). The white arrow 
highlights a cell of interest that appears at depth 24 μm in the TTP-knockdown OCE, but 
is not present in the same region of the OCE at depth 9 µm. By contrast, in the control 
OCE many GFP-expressing cells are present in the superficial layers, but GFP 
fluorescence rapidly decreases with increasing depth below the specimen surface, and 
no cancer cells are observed in the deep layers. 
Figure C.5B shows the number of SHG pixel counts over the entire field-of-view 
of the en-face images, as a function of depth below the surface. The pixel counts are 
averaged at each depth for 3 TTP-knockdown data cubes and 2 control data cubes, 
acquired on day 8 post-seeding, and error bars are equal to one standard deviation of the 
mean. More SHG is present in the top 20 µm of the TTP-knockdown OCE assays than 
the control assays. From 20-40µm below the surface, SHG levels in the TTP-knockdown 
assays drop below that of the control assays, and SHG rapidly decreases in the TTP-
knockdown assays deeper than 40 µm below the surface. This indicates the increased 
decay of the collagen matrix by TTP-knockdown cancer cells compared to control cells. 
Furthermore, the higher level of SHG in the superficial layers of TTP-knockdown assays 
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suggests increased cell invasion, compared to controls assays where a thick layer of 




Comparison of the OCE with Other Methods 
 Both two-dimensional (2D) and 3D approaches have been utilized to investigate 
cancer progression in vivo. An example of a 2D migration model is the scratch assay, 
where cancer cells growing in a tissue culture dish migrate into an area devoid of cells 
(201). Cancer cells in 2D culture lack cell-matrix interactions that influence the phenotype 
and protein expression of these cells, and therefore 3D approaches are preferred to study 
invasion (258). 
 Some 3D culture approaches use a collagen matrix composed of proteins derived 
from an extracellular matrix to create a structure to simulate invasion. In addition, an in 
vitro cell-layering approach to development of 3D tissues has been described (259).  
Synthetic matrix-based invasion assays are useful in vitro for preliminary studies to 
evaluate changes in the invasive phenotype after manipulating proteins of interest in cells, 
but have significant limitations including the absence of a basement membrane structure 
and lack of the structural complexity of the connective tissue. In addition to the inadequacy 
of many in vitro approaches, most mouse models of human HNSCC are also inadequate 
to investigate invasion because tumor cells are injected directly into the connective tissue, 
thereby bypassing the basement membrane of the surface epithelium. 
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 Some 3D cancer models emphasize the aggregation of cells and have a variety of 
advantages and disadvantages (260). A number of models depend on spontaneous 
aggregation of cells (261), but can only be adapted to study a limited array of cancer 
types. Microcarrier beads are inexpensive and support 3D structures grown in cell culture 
(262), but the spheroids generated are mostly made up of beads. Engineered scaffolds 
are expensive and difficult to use in culture, but are biodegradable and can be used in 
both in vivo and in vitro settings (263). 
 The OCE model is advantageous because the commercially available human-
derived dermal matrix is used. As demonstrated, live imaging and histopathological 
studies are feasible with the OCE model. A heterogeneous population of cells can be 
introduced in the OCE system. The system can be adapted to a wide variety of cell types, 
and AlloDerm® grafts can be used for both in vivo and in vitro studies. 
 
Potential Applications of the OCE Method 
 The OCE model described in this protocol provides an exciting opportunity to 
evaluate the invasive phenotypes of individual cancer cell lines in a 3D assay and to 
evaluate the impact of altered protein expression on invasion. Virtual histopathology of 
live cells on an OCE construct can be derived through sub-surface nonlinear optical 
microscopy to observe and quantify invasion of cancer cells (264, 265). Subsequently the 
constructs can be fixed for light microscopy, including immunohistochemistry studies. The 
OCE model can be adapted to study the progression of many tumor types by altering the 
cell lines and culture conditions used. 
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 Three dimensional culture systems that preserve cell-matrix interactions are 
indicated for regenerative tissue applications because they preserve stem cell 
phenotypes (266) and facilitate epithelial-mesenchymal transition (EMT) (267), which has 
been shown to mediate invasion of  HNSCC cells (79). Application of this imaging 
technique will be useful to optimize previously described protocols that generate 3D 
constructs to replicate normal tissue, such as normal oral (268) and airway (269) mucosa.  
In addition, adaptation of the imaging methodology described in this protocol may be an 
interesting application to view cellular changes in a recently published protocol describing 
viral infection of human tissue explants (270). 
 
Limitations of the OCE Method 
 The main advantages of the OCE method over other in vitro methodologies include 
the invasion of cancer cells in the connective tissue stroma after disruption of the 
basement membrane, thereby simulating intraoral HNSCC. In addition, the procedure 
allows for stratification of cultured cells and growth of the cells in a 3D setting with complex 
cell-cell and cell-matrix interactions. However, the OCE model has some limitations.  
HNSCC involves multiple epithelial-stromal interactions, including interactions between 
cancer cells and fibroblasts, blood vessels, immune cells and nerves.  Although the OCE 
construct described here does not contain other cell types involved in the disease 
process, the model can be modified to add different cell types. Because the OCE method 
takes several days, it is necessary to transfect cells with a GFP tag rather than use a 
fluorescent dye, which will degrade over the duration of the experiment. The model also 
requires significant optimization. The number of cells, cell culture conditions, 
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concentration of chemoattractant used, and the time of harvesting all must be determined 
during optimization studies. Sub-surface imaging on sequential days helps to determine 
optimal timepoints for harvesting the OCE for histopathological studies. 
 In summary, the OCE method is a novel approach of preparing an in vitro model 
of HNSCC using human cancer cell lines and decellularized human cadaveric dermis.  
Furthermore, the in vivo imaging method described here and the comparison to histology 







Figure C.1: Histological comparison of HNSCC and OCE model. A. A lesion that 
presented clinically as a leukoplakia was subsequently diagnosed as HNSCC. B. 
Formalin-fixed OCE and OCE tissues in culture are shown.  Histology of human HNSCC 
(C) and of an OCE (D) shows invasion in both specimens. Arrowheads point out the 





Figure C.2: Overview of OCE protocol. HNSCC cells are plated on hydrated 
decellularized human cadaveric tissue coated with collagen IV on day 1. On day 3 the 
OCE is brought to the liquid-air interface and invasion of HNSCC cells occurs through 
day 5, when sub-surface imaging of live cells is performed. The OCE tissues are then 





Figure C.3: Comparison of OCE histology produced via hematoxylin-eosin staining 
and nonlinear optical microscopic molecular imaging. The vertical cross-section 
image of the OCE with control HNSCC cells (A) shows cells forming a layer on top of the 
tissue scaffold with little invasion below the surface, whereas the OCE with HNSCC cells 
with downregulated TTP (B) shows cells invading below the surface, forming nests of 
cells within the connective tissue. The quality of vertical cross-section images is degraded 
as compared to en-face images, due to the inherent poorer resolution of non-linear optical 
microscopy in the axial dimension, and scattering effects when imaging deep below the 





Figure C.4: En-face image montage of UM-SCC-1-shTTP cells in the OCE at 3 µm 
depth increments below the surface of the OCE. GFP-expressing cells form strings of 
cells invading below the surface of the assay, visualized as green rings that are apparent 





Figure C.5: Vertical stack of depth-resolved en-face nonlinear optical microscopic 
molecular images of OCE immunofluorescence assays, and quantification of SHG 
pixel counts as a function of depth. Representative data cube of a 3D stack of en-face 
images taken of control and TTP-knockdown OCE assays 7 days post-seeding are shown 
(A). Green indicates 2-photon excited fluorescence from GFP-expressing UM-SCC-1 
cells. Blue shows second harmonic generation (SHG) from collagen, in decellularized 
human cadaveric dermis scaffold of the OCE. Whereas the control cells (left) are no 
longer visible in the deeper tissues of the dermis, cells with downregulated TTP (right) 
are still visible at 24 μm below the surface, indicating that these cells are invading through 
the tissue scaffold. The white arrow highlights a region of interest where an invading cell 
is present at a depth of 24 µm, but is not present in the same region of the OCE at a depth 
of 9 µm. Bars=50 μm. The number of SHG pixel counts over the entire field-of-view of the 
en-face images, as a function of depth below the surface, was quantified for 3 TTP-
knockdown data cubes and 2 control data cubes of OCE assays imaged 8 days post-
seeding (B). TTP-knockdown assays have higher SHG content in superficial layers than 
control assays, but rapidly lose SHG signal in the deeper layers compared with control 




The Chick CAM Assay, a Novel Model of Head and Neck Squamous Cell 
Carcinoma 
Appendix D is adapted from a published manuscript (66). 
 
INTRODUCTION 
 Although the CAM assay has been in use for many years, the benefits of studying 
tumor invasion using this model are more recently recognized. The CAM is a highly 
vascularized membrane that is located directly below the egg shell. This makes the CAM 
easy to access through a small hole in the egg shell. The CAM is also made up primarily 
of collagen IV, which simulates the basement membrane of human oral epithelium. The 
CAM assay has been used to measure invasion of a variety of cell types, including 
fibroblasts (271) and several types of cancer cells, including melanoma cells (272-274).   
 We propose that the chick embryo is an excellent model of invasion and metastasis 
of human HNSCC. The CAM consists of the chorionic epithelium separated from the 
underlying allantoic membrane by connective tissue. The chorionic epithelium is 
separated from the connective tissue by an epithelial-derived basement membrane that 
contains collagen IV (275). The cellular connective tissue contains types I and III collagen 
and blood vessels. In this model, HNSCC cells are seeded on top of the CAM and allowed 
to invade. Thus, the CAM recapitulates intraoral human HNSCC progression including 
disruption    of    the    basement    membrane,   complexity   of   the   connective   tissue, 
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angiogenesis   and   metastasis. Even the histopathologic features simulate invasion 
observed in HNSCC. Destruction of the basement membrane can be easily visualized 
and tumor growth, invasion into the connective tissue, and metastasis can be accurately 
quantified, making this a valuable model for investigating progression of HNSCC.   
 In this study, we describe for the first time the use of the CAM to investigate multiple 
tumorigenic phenotypes simultaneously, including tumor growth, invasion, metastasis 
and angiogenesis in HNSCC. Recently, we showed that EZH2 (enhancer of zeste 
homolog 2), the histone methyltransferase, promotes progression of HNSCC by inducing 
multiple cancer phenotypes, likely via methylation of multiple tumor suppressor genes 
(71, 75). In order to develop the CAM model, we investigated the role of EZH2 in tumor 
growth, angiogenesis, invasion and metastasis in vivo. In addition, we show the role of 
EZH2 in epithelial-mesenchymal transition (EMT) in mouse tumors, CAM tumors and in 
HNSCC cell lines. Overall, we are able to establish the CAM model of HNSCC and 




CAM in vivo Model of HNSCC Tumor Progression. The University of Michigan Unit for 
Laboratory Animal Medicine was consulted regarding ethical use of the chicken embryo 
CAM for experiments.   
 
Dropping the CAM. Fertilized commercial Lohmann White Leghorn eggs were 
obtained from the Michigan State University Department of Animal Sciences Poultry 
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Farm.  Prior to hatching, the eggs were maintained at 24ºC.  Eggs were subsequently 
“hatched” in a humidified incubator (Digital Sportsman Incubator; G.Q.F. 
Manufacturing) at 38°C with 60% humidity. The initial day of incubation is considered 
day 0.  On day 11, the following structures were labeled on the egg using the ACE 
light source (Trevigen Inc.): large blood vessel, umbilical cord, air sac, small square 
window for the artificial air sac generation and a large window area for seeding cancer 
cells. Using a Dremel 1100-N/25 7.2- Volt Stylus Lithium-Ion Cordless Rota (Robert 
Bosch Tool Company), a 1 cm2 window was drilled on the top of the egg shell, 
maintaining the outer egg shell membrane. A pinpoint hole was prepared on the side 
of the egg at the location of the airsac.  Twenty five microliters of HBSS (Invitrogen, 
Life Technologies) was added on top of the 1 cm2 window at the top of the egg.  Then, 
using a 30½ gauge needle, the outer eggshell membrane was punctured at the 
location of the window so that the buffer separates the outer eggshell membrane from 
the CAM. The small pinpoint hole was vacuumed using a Pasteur pipet bulb, causing 
the air bubble to move to the window and allowing the CAM to drop. Then the egg 
shell was drilled in the large window area and blunt ended forceps were used to peel 
off the eggshell membrane without disturbing the CAM. The large square hole was 
covered with parafilm and the egg was place in the incubator without shaking. 
 
Seeding HNSCC Cells. HNSCC cells (1x106) were resuspended in 5 µl of Hank’s 
Balanced Salt Solution (HBSS). The pipette was used to make a bead of cell and 
medium that is dropped onto the CAM surface, without allowing the pipette tip to touch 
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the CAM. The square window on the egg was sealed with Tegaderm HP Transparent 
Film Dressing. The eggs were incubated without shaking for approximately 3 days.  
 
Harvesting the CAM. Using a needle and syringe, a small amount of 4% 
paraformaldehyde was injected onto the surface of the CAM. Dissecting scissors were 
used to cut open the large window to visualize the CAM and the tumor. Using scissors 
and a pair of forceps, each CAM was lifted and cut around the tumor. The tumors and 
surrounding CAM were transferred to a 6-well dish containing 4% paraformaldehyde 
and incubated at 4°C for 4 hours. The CAMs were transferred to cold 30% sucrose 
and stored overnight at 4°C. The next day, the CAMs were embedded in Optimal 
Cutting Temperature Compound (Tissue-Tek) and frozen at -80°C until sectioning and 
staining. 8-10 µm tissue sections were fixed in 4% paraformaldehyde for 5 minutes 
followed by staining with hematoxylin and eosin. 
 
Endpoint Assays. For tumor growth and angiogenesis studies, suspensions of 5x105 
HNSCC cells with stable knockdown of EZH2 or controls were suspended in 5 µl 
HBSS and plated on the upper CAM. The window on the egg shell was resealed with 
adhesive tape and eggs were returned to the incubator for 48 hours before harvesting 
the tumor (n=5 chick embryos per experimental group). Surface area of the tumors 
was quantified using ImageJ software and statistically compared between control 
tumors and tumors with stable EZH2 knockdown. Angiogenesis was also quantified 
using red color density within 200 µm of tumors in images using ImageJ software 
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(http://rsbweb.nih.gov/ij/) with the Colour Threshold plugin provided through the 
University of Birmingham School of Dentistry website.  
(http://www.dentistry.bham.ac.uk/landinig/software/software.html).  
 For invasion assays, cells were dyed with the lipophilic tracer, DiO (a 
dialkylcarbocyanine derivative) prior to experiments. Tumor sections were imaged at 20x 
and invasive islands were quantified for each image. Statistical analysis to compare the 
number of invasive islands was performed.  
 For collagen IV staining, the frozen tissue sections were fixed in methanol, washed in 
PBS and blocked with 0.1% BSA, 10% NGS in PBS for 30-60 minutes. The collagen IV 
antibody was diluted 1:1 in 0.1% BSA, 5% NGS and incubated on the tissue sections for 
2 hours. The coverslips were mounted with Prolong Gold Antifade reagent with DAPI 
(Invitrogen, Life Technologies). 
 For metastasis experiments, HNSCC cells were plated as described for invasion 
studies at day 8. The lower CAM, liver and lungs were collected at day 16.  Human DNA 
was quantified from DNA extracted from the harvested tissues using alu-PCR to compare 
metastasis from control and EZH2 knockdown tumors. To generate the standard curve, 
genomic DNA from human HNSCC cells (each human cell contains 6.6 pg of DNA) was 
mixed with 1 µg of chicken genomic DNA in logarithmically increasing concentrations as 
0.1, 1.0, 10, 100, 1000, and 10000 cells. PCR was performed in triplicate for each of the 
standards as well as the experimental samples. The absolute number of metastatic 
human cells in the experimental sample was calculated from the standard curve using 




Cell Culture. The HNSCC cell line, UM-SCC-29 (from T. Carey), used in this study was 
validated by genotyping at the University of Michigan DNA Sequencing Core, and cultured 
as described (202, 246). Cells were maintained in DMEM (Gibco, Life Technologies) 
supplemented with 10% FBS and 1% PenStrep. EZH2 in HNSCC cells was stably 
downregulated as described (71); scrambled shRNA (shSCR) was used for control cells 
and shEZH2 for EZH2 knockdown cells (Open Biosystems). Cells were selected with 
puromycin (Sigma-Aldrich).  
 
Immunoblot Analysis. Immunoblot analysis was performed as previously described 
(197). 1% NP40 lysis buffer was used to lyse HNSCC cells. EZH2 (BD Biosciences, San 
Jose, CA) and GAPDH (Millipore) primary antibodies were used. The secondary antibody 
used was horseradish peroxidase-conjugated anti-mouse (Jackson Immuno-Research 
Laboratories). SuperSignal West Pico Chemiluminescent system (Thermo Scientific) was 
use to visualize immunoreactive proteins and ImageJ software was used to quantify 
signal intensity (http://rsbweb.nih.gov/ij/). 
 
Immunohistochemistry.  Immunohistochemistry of tissue sections was performed as 
described (246). The primary antibodies used were vimentin (Proteintech) and E-cadherin 
(BD Biosciences) and biotinylated goat anti-rabbit and biotinylated goat anti-mouse 
secondary antibodies were used (Biocare Medical). Imaging of cells was performed at the 
Microscopy and Image Analysis Core at the University of Michigan on an Olympus BX-




Murine Model of HNSCC Using Subcutaneous Injection.  Athymic nude mice were 
used as described (276). UM-SCC-29 cells (1 x 106) were stably transduced with shSCR 
or shEZH2 and injected subcutaneously to assess tumor growth (272). Histopathologic 
analysis of these tumors is shown in the present study. 
 
Immunofluorescence Detection of Vimentin and E-cadherin. Cells were labeled with 
vimentin (Proteintech) and E-cadherin (BD Scientific) primary antibodies diluted in 0.3% 
triton X-100 overnight at 4ºC, washed, and incubated for 2 hours at room temperature in 
an appropriate conjugated secondary antibody, washed and incubated in DAPI (1:3000) 
for 3 minutes. Imaging of cells was performed at the Microscopy and Image Analysis Core 
at the University of Michigan on an Olympus BX-51 microscope. Representative fields 
were imaged at 100x. 
 
Data Analysis. Statistical analysis was performed using Student's t-test using GraphPad 
Prism (GraphPad Software). A P-value of <0.05 was accepted as statistically significant. 
 
RESULTS 
EZH2 Enhances HNSCC Tumor Size on the CAM 
 Using the CAM in vivo model, we investigated the impact of EZH2 on tumor growth in 
HNSCC. EZH2 is a master regulatory gene in HNSCC that inhibits expression of tumor 
suppressor genes (71). UM-SCC-29 cells with stable knockdown of EZH2 (UM-SCC-29-
shEZH2) and corresponding control cells with empty vector (UM-SCC-29-shSCR) were 
seeded on the CAM (n = 5 for each group). After 48 hours, the upper CAM was harvested 
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from each chick embryo and the surface area of the tumors was quantified (Figure D.1A).  
shRNA-mediated EZH2 knockdown was confirmed by immunoblot (Figure D.1B).  UM-
SCC-29-shEZH2 cells produced tumors that were significantly smaller than tumors 
generated by control cells (P = 0.0460, Figures D.1A, dashed lines and Figure D.1C). 
Although the difference in size between control and EZH2-deficient tumors is significant, 
the variability in tumor size led to a higher p-value than anticipated. A larger sample size 
may have provided a lower p-value to better reflect the difference in tumor size between 
the groups. Additionally, because since some tumors appear to be more bulky than 
others, 3D analysis of tumor size may provide a more consistent estimation of tumor size. 
 
EZH2 Promotes Angiogenesis of HNSCC Tumors on the CAM 
 To investigate the impact of EZH2 on tumor-associated angiogenesis, the area of 
blood vessels within 200 µm of the tumors were quantified. shEZH2 tumors had 
decreased blood vessel area adjacent to tumors compared to controls, indicating 
decreased angiogenesis of the tumors (P = 0.0348, Figures D.1A, arrows and Figure 
D.1D).  
 
EZH2 Enhances Basement Membrane Disruption and Invasion of HNSCC Tumors on 
the CAM 
 Tumors produced by UM-SCC-29-shSCR and –shEZH2 were harvested and 
sectioned. Collagen IV staining was performed on the section to visualize disruption of 
the basement membrane on the upper CAM. Tumors produced with UM-SCC-29-shSCR 
control cells showed more disruption of the basement membrane than tumors with stable 
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knockdown of EZH2 (Figure D.2A). This correlated with an increased number of invasive 
tumor islands in UM-SCC-29-shSCR tumors than in tumors from cells with 
downregulation of EZH2 (Figure D.2B, P = 0.0053).  
 
EZH2 Promotes a Mesenchymal Phenotype of HNSCC In Vitro and of Murine and CAM 
Tumors 
 Previously, we established that downregulation of EZH2 inhibited tumor growth in 
mice (71). Control tumors, expressing high EZH2, exhibited an aggressive phenotype 
including cells, with large nuclei, little cytoplasm, and spindled morphology (arrows), 
invading skeletal muscle (arrowheads) (Figure D.3A, upper panel). In contrast, tumors 
with EZH2 knockdown (Figure D.3A, lower panel) exhibited well differentiated epithelial 
cells (keratin formation; arrowheads) with increased cytoplasm (arrows), a less 
aggressive, more epithelioid phenotype. To verify the impact of EZH2 on epithelial-
mesenchymal transition, UM-SCC-29-shEZH2 and -shSCR cells were plated at 60% 
confluence and fixed. Immunofluorescence labeling of vimentin and E-cadherin were 
performed, and 5 representative fields were imaged at 100x (Figure D.3B). Intensity of 
fluorescence was quantified and normalized to the average intensity of shSCR cells.  
Control cells have a more mesenchymal phenotype with increased vimentin (P < 0.001) 
and decreased E-cadherin (p=0.0342) compared to cells with EZH2 knockdown (Figure 
D.3B). These findings are consistent with EZH2 inducing an EMT phenotype. In addition, 
immunohistochemistry was performed for vimentin and E-cadherin expression on CAM 
tumor sections from shSCR and shEZH2 treated cells (Figure D.3C). Tumors with EZH2 
152 
 
knockdown had decreased vimentin expression (arrows) and higher E-cadherin staining 
(arrows) than control tumors. 
  
EZH2 Promotes Metastasis of HNSCC Tumor Cells on the CAM 
 The invasive phenotype of tumor cells facilitates extension into the surrounding 
structures and spread to distant sites (metastasis) via the blood vessels. In the CAM 
model, metastasis requires invasion of cells through the basement membrane of the 
surface epithelium and into the blood vessels. Since EZH2 promotes invasion, we also 
investigated its effect on metastasis using the CAM model. UM-SCC-29-shSCR and 
shEZH2 cells were incubated on the CAM of day 7 chick embryos. The eggs were 
incubated until day 15, when the lower CAM and liver of the developing chick were 
harvested. The metastasized human cells in the chicken background were quantified as 
described by qPCR for amplification of human Alu sequences (85, 277), which eliminates 
cross-reactivity with chicken DNA. When using control UM-SCC-29 cells, metastases 
were detected in all lower CAM specimens and 4/5 of the livers of the developing chicks. 
However, when using cells with reduced EZH2 expression, no metastases were detected 




 Over the past decade, the histone methyltransferase EZH2 has emerged as a key 
player in tumor progression in many cancer types, including HNSCC (71) breast (278, 
279), bronchial (280), lung (281) and prostate (282). Overexpression of EZH2 is often 
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linked to poor prognosis and advanced disease (283). EZH2 expression is also correlated 
to increased angiogenesis in tumors (284), in part due to paracrine signaling between 
tumor cells and associated vasculature (285). EZH2 has also been shown to have a role 
in cancer stem cell maintenance (286).   
 Our laboratory recently showed that EZH2 contributes to HNSCC progression by 
hypermethylating the promoter region of the tumor suppressor Rap1GAP (71, 75). We 
found that EZH2 is upregulated in HNSCC cell lines compared to normal keratinocytes, 
and that EZH2 promotes tumor growth in vitro and in vivo in the mouse model. In our 
previous study we also evaluated the role of EZH2 in invasion using in vitro assays, and 
found that EZH2 expression is highly correlated with HNSCC cell invasion (71). However, 
we were unable to evaluate the impact of EZH2 on early invasive phenotypes i.e. 
destruction of the basement membrane of surface epithelium since in the mouse model, 
tumor cells are injected directly into the connective tissue. Invasion beyond the basement 
membrane is required for transformation of a pre-cancerous lesion (epithelial dysplasia) 
to HNSCC (287). 
 In our current study, we chose the CAM in vivo model of tumor progression to 
validate our previous in vitro findings about the role of EZH2 in tumor invasion. In this 
study, which is to our knowledge the first study to describe the use of the CAM model to 
investigate tumor progression of HNSCC, we show that downregulation of EZH2 in 
HNSCC cells inhibits destruction of the basement membrane and decreases invasion in 




 There are many benefits of using the CAM to study tumor progression (288). The 
CAM assay is completed in a short time period and is relatively inexpensive compared to 
most in vivo models. The lack of a mature immune system at the time the assay is 
performed allows for use of different cell types, and cells from different species. Because 
the chicken embryo has been used scientifically for centuries, the system is well 
described in the literature. Limitations of the assay include the extensive optimization and 
the large number of eggs that are required to obtain consistent results. As in other in vivo 
systems, tumors produced on the CAM exhibit some variability. Therefore, it is 
appropriate to use a sample size of at least 5 eggs per group to characterize differences. 
 In addition to establishing the CAM model of HNSCC tumor progression, we also 
evaluated the role of EZH2 expression on the histopathological presentation of HNSCC 
tumors and on the expression of the EMT markers vimentin and E-cadherin. EMT is a 
process by which non-motile cells lose contact with neighboring cells and become more 
motile (180). EMT has been shown to promote HNSCC invasion, metastasis and tumor 
stemness (287). While control cells produced aggressive, mesenchymal-like tumors in 
vivo, tumors produced from HNSCC cells with reduced EZH2 expression had a more 
epithelial-like appearance, consistent with a less aggressive tumor. In addition, 
knockdown of EZH2 leads to decreased vimentin and increased E-cadherin expression 
in HNSCC cells and CAM tumors. These findings indicate that EZH2 plays a role in 
mediating EMT in the HNSCC cell line UM-SCC-29. We have previously shown that 
EZH2-mediated invasion is not dependent on E-cadherin alteration in the E-cadherin 
deficient cell line, OSCC3. Therefore, other factors that are still under investigation have 
a role in EZH2-mediated EMT, independent of E-cadherin (75). 
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 Our study investigating the role of EZH2 in tumor progression is the first to describe 
the use of the CAM model to study progression of HNSCC. The CAM model can be used 
to investigate tumor size, angiogenesis, invasion and metastasis of HNSCC. In addition, 
we show that knockdown of EZH2 expression in HNSCC cells leads to less aggressive 
tumors with a more epithelial-like phenotype. Together, these studies highlight the 
emerging role of EZH2 in HNSCC progression. Future studies will elucidate the 
mechanistic role of EZH2 in EMT. In addition, the role of EZH2 inhibitors should be 





Figure D.1: EZH2 promotes tumor growth and angiogenesis. Fluorescently-labeled 
UM-SCC-29-SCR and –shEZH2 cells were seeded on the CAM. The upper CAM and 
tumors were collected 2 days later to analyze tumor growth and angiogenesis.  White 
arrowheads show blood vessel growth approximating tumor (A, brightfield images).  
Dashed lines outline tumor generated from HNSCC cells on CAM (A, GFP images).  
Yellow arrowheads identify tumor islands migrating from primary tumor (A, GFP images).  
shRNA-mediated EZH2 knockdown was confirmed by immunoblot (B). The average 
tumor growth and blood vessel density was calculated for both shSCR and shEZH2 
tumors (n=5 for each group). Tumor size (C) and angiogenesis (D) were significantly 






Figure D.2:  EZH2 promotes destruction of the basement membrane and invasion. 
Arrows (A) identify the basement membrane structure and tumor cells are labeled green.  
shSCR tumor cells are highly proliferative and invasive, and destroy the basement 
membrane structure, but shEZH2 cells do not disrupt the basement membrane. Fewer 







Figure D.3: EZH2 promotes EMT and metastasis of HNSCC. A. Histopathologic 
appearance of HNSCC tumors induced by UM-SCC-29-shSCR and -shEZH2 cells in 
mice. Control tumors (upper panel) exhibit an aggressive and mesenchymal phenotype 
with large nuclei, little cytoplasm and spindled morphology (arrows) and invasion into 
skeletal muscle (arrowheads). Knockdown of EZH2 (lower panel) leads to more 
epitheloid, well-differentiated tumors containing cells with increased cytoplasm (arrows) 
and keratin formation (arrowheads). To verify the impact of EZH2 on epithelial-
mesenchymal transition, immunofluorescent labeling of vimentin and E-cadherin were 
performed and representative fields were imaged at 100x (B).  Relative fluorescence was 
measured for 5 representative fields and quantified. Control cells have a more 
mesenchymal phenotype with increased vimentin (p<0.001) and decreased E-cadherin 
(P=0.0342) compared to cells with EZH2 knockdown.  HNSCC cells were seeded on the 
CAM and the lower CAM and liver were collected at day 15.  Immunohistochemistry of 
EMT markers on CAM sections shows decreased vimentin (arrows, C) and more intense 
E-cadherin expression of tumor cells (arrows, C) for shEZH2 tumors compared to shSCR 
tumors.  Metastases were observed to both the lower CAM and liver for controls but no 





Personalized Medicine Strategies for Cancer Treatment: Lessons Learned from 
Tumor Antigens 
Appendix E is adapted from a published manuscript (248), which is a commentary of a 
published research article (289). 
  
HNSCC is among the 10 most common cancers in the world. Nearly half of the 
600,000 individuals affected globally will die of the disease within 5 years of diagnosis 
(1). If HNSCC is detected early, the prognosis is favorable. Due to late detection, most 
patients are at risk for recurrence and metastasis, which contribute to morbidity (1). To 
improve patient survival, robust screening tests are necessary to discover HNSCC at an 
early stage. Moreover, a biomarker-based approach may assist in management of 
HNSCC to improved treatment outcomes (290). 
 Tumor antigens are proteins specifically expressed by tumor cells and recognized 
by the immune system of the host (291). The immune response can be characterized to 
identify a cancer-specific signature (292). Novel cancer-specific autoantibody signatures 
can be used as a screening tool for early detection, allowing for effective treatment. 
Moreover, because cancers are heterogenic diseases, disparities in  treatment response, 
160 
 
for example resistance or sensitivity to chemotherapy, are likely linked to a specific tumor 
antigen repertoire. With the information about the tumor provided by its antigen signature, 
the most appropriate targeted treatment can be selected. Our laboratory recently explored 
the immune response to identify a novel antibody signature specific to HNSCC (289). 
Overall, the major findings of this study were 3-fold. First, we used phage display and a 
liquid ELISA assay to develop an antibody signature for HNSCC. Next, using an in silico 
approach, we nominated tumor antigens for functional validation. Finally, we validated 
L23 as an oncogene through multiple in vivo and in vitro approaches. 
 Using phage display to enrich the antibody response to tumor antigens, we 
identified previously undescribed tumor antigens in HNSCC. In the phage display 
technique, bacteriophage vectors are used to display tumor antigens. Using these phages 
as bait, antibodies specific for HNSCC were enriched via biopanning. An immunomic 
array was constructed from the enriched phages and used to screen additional control 
and HNSCC sera. The clones most specific for HNSCC were validated by the Luminex 
200™ system. Ultimately, we identified a HNSCC-specific signature including in-frame 
proteins, one of which was L23. Finally, using in vitro and in vivo approaches, we validated 
L23 as an oncogene. An important aspect of the recent study was the use phage libraries 
from tumors at different sites to detect a HNSCC-specific signature.  
 The potential of personalized medicine strategies will be harnessed when efficient 
and reliable methods of tumor detection and treatment selection are developed. Routine 
screening of patient serum for a cancer signature would facilitate early detection. Figure 
E.1 shows an overview of a screening and personalized treatment strategy based on the 
antibody signature in serum. In the proposed strategy, a “master immunomic array” would 
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include tumor antigens specific for different cancers. This would detect a cancer-specific 
antibody signature using serum collected during a routine physical exam. Thus, tumor-
specific antibodies present in sera will assist in early detection similarly to prostate-
specific antigen (PSA), which has assisted in early diagnosis of prostate cancer (293). 
 The cancer-antibody signature may also inform treatment selection and predict 
treatment progression. For example, an autoantibody signature for prostate cancer is 
apparently a more specific screening tool than PSA, and may assist in guiding treatment 
strategies (294, 295). 
 Finally, antibody signatures will help identify novel proteins involved in tumor 
progression, i.e. which early stage lesions although treated appropriately, will progress 
aggressively. Identification of these tumors would inform selection of aggressive 
treatment strategies at an early stage. In our recent study, we validated the role of L23 
as an oncogene in HNSCC. The roles that other HNSCC-specific proteins have in tumor 
progression are unknown. As we strive to achieve personalized medicine based 
strategies for cancer therapy, it is exciting to consider that some tumor antigens may be 
novel therapeutic targets. Perhaps through improved screening tools and novel 
therapeutic approaches based on HNSCC tumor antigens, we will see an improvement 
in survival from this devastating disease. 
 





Figure E.1: An immunomics approach for early detection and personalized 
treatment strategies for cancer. A routine blood draw collected from individuals in an 
asymptomatic population is screened using a cancer immunomic array.  Individuals with 
different types of cancer are identified at an early stage with a positive serum test. In 
addition, within each cancer-specific signature, chemosensitive and chemoresistant 
signatures are identified by the array. These signatures inform healthcare providers of the 
specific treatment needs of each patient, allowing for a personalized treatment strategy 
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